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ABSTRACT
The Association of Markers of Endothelial Dysfunction and Incident
Diabetes Mellitus, Hypertension, Chronic Kidney Disease and Cardiovascular Mortality
Loretta R Cain
In recent years several mechanistic animal studies have proposed new insights, including
the role of endothelial dysfunction, in the pathogenesis of common cardiometabolic disorders
such as diabetes mellitus, hypertension, chronic kidney disease (CKD) and cardiovascular
disease (CVD). However, few studies in humans have followed up these emerging leads from
animal models. Because traditional risk factors have been shown not to completely explain all
the observed risk of cardiometabolic outcomes in the general population, there is a need to
examine novel mechanisms such as endothelial dysfunction in population-based studies, so as to
identify new ways of preventing and/or treating these diseases. In this context, we examined the
novel hypothesis that higher serum levels of markers of endothelial dysfunction, including
soluble vascular cell adhesion molecule-1 (sVCAM-1) and soluble intercellular adhesion
molecule-1 (sICAM-1), are positively associated with the risk of developing diabetes mellitus,
hypertension, CKD and cardiovascular mortality in four separate studies. We measured sVCAM1 and sICAM-1 levels from stored serum in a random sample (n=1793) of baseline participants
from the Beaver Dam Eye Study, a population-based, longitudinal cohort study of n=4926
subjects (55% women), aged ≥43 years from Beaver Dam, Wisconsin. The main outcomes of
interest were 15 year incidence of diabetes mellitus, hypertension, CKD and CVD mortality
occurring between the baseline examination at 1988-90 to the end of mortality follow-up at Dec
31, 2002. During the stated follow-up period, 156 subjects developed diabetes mellitus, 257
subjects developed hypertension, 269 subjects developed CKD and 212 subjects died of
cardiovascular causes. We found that serum levels of sVCAM-1 and SICAM-1 are positively
related to diabetes mellitus in men only (hazards ratio [HR] (95% confidence interval [CI]) =2.29
[1.18-4.44] for sVCAM-1 in men), and with hypertension (HR=2.14 [1.42-3.23] for sVCAM-1)
and CVD mortality (HR= 1.79 [1.17-2.76] for sICAM-1) in both men and women. In contrast,
markers of endothelial dysfunction were not found to be related to CKD. In conclusion, we have
shown that serum markers of endothelial dysfunction are associated with higher risk of
developing diabetes mellitus, hypertension and CVD mortality, but not with CKD.
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Chapter 1

Introduction
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1.1 CARDIOVASCULAR DISEASE, DIABETES, HYPERTENSION, CHRONIC
KIDNEY DISEASE AND THE NEED FOR NOVEL MARKERS
According to the Centers for Disease Control and Prevention (CDC), 2.4 million deaths
occurred in the United States, with cardiovascular disease (CVD) being the number one cause of
death in the United States.1 Risk factors for CVD mortality include age,2 low physical activity,3
diabetes mellitus,4 hypertension,5 coronary heart disease,4 and CKD.6 However, these traditional
risk factors do not explain all the CVD risk in the general population and therefore there is a
need to identify novel risk factors. In this context, mechanistic animal studies have proposed new
molecular insights into the pathogenesis of CVD, such as the role of inflammation, and
endothelial dysfunction.7 There is a need to examine these novel pathogenetic mechanisms in
population-based studies with an aim of identifying novel predictive markers and also to advance
our understanding of CVD pathogenesis in humans.
Diabetes mellitus is a known risk factor for CVD,8 and according to the 2007 National
Diabetes Fact Sheet by CDC, 23.6 million and adults in the United States (7.8% of the
population) have diabetes.9 Known risk factors for diabetes include increasing age,10 higher
body mass index (BMI),11 hypertension,12 central obesity,13 insulin resistance7 and dietary
factors.14 Emerging evidence suggest that endothelial dysfunction may be a causative factor in
the development of diabetes mellitus also.7
Similarly, hypertension is a known risk factor for cardiovascular disease, including
myocardial infarction, heart failure and stroke.15 A recent study comparing two consecutive
national surveys reported an increase in the prevalence of hypertension from 23.9% in 19881994 to 29.0% in 2007-2008. 16 Risk factors for hypertension include a family history of
hypertension17, age18-20, gender21,22, physical inactivity23-25, high-salt intake26-28,
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overweight/obesity20,29,30, alcohol20, smoking30,31 and diabetes mellitus15,19,32 However, these
traditional risk factors may not account for all the observed risk of hypertension in the general
population.33 In this context, based on predominantly data from animal studies,34 endothelial
dysfunction is now being proposed as a novel mechanism that may be involved in the
development of hypertension.
Chronic kidney disease (CKD) is recognized as a strong risk factor for incident CVD35,
including coronary artery disease and stroke, and it also independently predicts CVD mortality.36
Identifying risk factors for CKD are therefore important in preventing CVD.35 A recent study
comparing two consecutive national surveys reported an increase in the prevalence of CKD
between 1988-1994 and 1999-2004 suggesting it to be a growing public health problem.37
Diabetes mellitus 38,39 and hypertension 39-44 have been consistently shown to be important risk
factors in the development of kidney disease. Studies have shown that several of the known
cardiovascular risk factors are also related to the development of CKD, including advancing
age,38,39,45,46 male sex,39-44 obesity,39-44,47 smoking,39,44,48 high triglycerides,49 low high-density
lipoprotein (HDL) cholesterol,39,49,50 and a mild reduction in GFR at baseline.39 However, these
traditional risk factors do not account for all the observed CKD risk in the general
population.39,51,52 Therefore studies are needed to examine the role of new predictors in the
development of CKD, including markers of endothelial dysfunction.

1.2 MARKERS OF ENDOTHELIAL DYSFUNCTION
The vascular endothelium is involved in a variety of key processes important to human
health and disease, including control of coagulation,53 fibrinolysis.53,54 vascular tone53,55 and
growth,55 immune response53,55 and oxidative stress.54,56 Endothelial dysfunction has been found
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to be closely related to insulin resistance,7,57 elevated levels of inflammatory markers,7,58
impaired function of lipoprotein lipase (contributing to high triglycerides and low HDL
cholesterol levels,7,58 impaired nitric oxide release58 and endothelium dependent vasodilation.58
Studies suggest that endothelial dysfunction is associated with risk factors and processes
associated with diabetes mellitus, such as hyperglycemia,59 inflammation,59 and insulin
resistance.7,57 One of the well-known vasodilators produced in the endothelium is nitric oxide
(NO) whose production is decreased due to endothelial dysfunction, 60 resulting from reduced
activity of endothelial NO (eNOS). Early stages of endothelial dysfunction are related to
increased production of reactive oxygen species (ROS) which in turn can cause more damage to
endothelial and vascular function. 61 ROS are now considered to be a major risk factor in the
development of insulin resistance, diabetes mellitus, hypertension, and CVD.62
Endothelial dysfunction may cause hypertension by impairing the vasodilator mechanism
of NO (which is also called endothelium-derived relaxing factor), subsequently causing elevated
blood pressure.63 Endothelial dysfunction may also be related to other mechanisms involved in
the development of hypertension, including insulin resistance64, systemic inflammation65 and
hyperuricemia.66
Endothelial dysfunction is present in end-stage renal disease.67,68 Biomarkers of
endothelial dysfunction, including circulating adhesion molecules VCAM-1, ICAM-1, and Eselectin are shown to be elevated even in less advanced stages of kidney disease.67,69,70
Endothelin-1 (ET-1), an endothelium-derived growth factor, of both renal mesangial and extrarenal vascular origin and its interaction with angiotensin-II are implicated in the progression of
renal disease.71 For example, Koobi et al.72 showed that Angiotensin II type 1 (AT1) receptor
blockade in nephrectomized rats significantly reduced the vasoconstriction response in relation
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to Endothelin-1 administration. Angiotensin-II, a central molecule in the initiation and
progression of chronic renal disease49,73 is closely related to endothelial function and
inflammation74 and treatment with angiotensin converting enzyme inhibitors have been shown to
lower circulating biomarker levels of inflammation and endothelial dysfunction75. These
findings suggest that endothelial dysfunction may precede and can predict the development of
CKD.
Animal studies show that endothelial dysfunction may have a causative role in the
development of cardiovascular disease.76 The intact, healthy endothelium secretes various
cardio-protective substances including nitric oxide, which diffuses to surrounding tissues and
cells, relaxing smooth-muscle cells and preventing platelet adhesion and aggregation, preventing
expression of adhesion molecules, leukocyte adhesion and migration into the arterial wall and
arterial smooth muscle cell proliferation77. Conversely, early stages of endothelial dysfunction is
characterized by increased formation of reactive oxygen species and increased expression of
adhesion molecules such as sVCAM-1 and sICAM-1, which can react with NO forming
peroxynitrate78, reducing NO bioavailability, which over the long run may be involved in
increased risk of cardiovascular disease79.
Because most methods of assessing endothelial dysfunction are invasive and are not
suitable for large-scaled epidemiological studies,80 circulating levels of cellular adhesion
molecules such as such as intercellular adhesion molecule 1 (ICAM-1), and vascular cell
adhesion molecule 1 (VCAM-1) are highly specific and valid markers of atherosclerosis–related
endothelial dysfunction and have been used extensively in epidemiologic studies that utilized
stored biospecimen 81,82
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1.3 GAPS IN THE LITERATURE
The few previous studies exploring the relationship between endothelial dysfunction and
diabetes mellitus have reported contrasting relationships by gender, with some studies finding an
association only in men83,84 and others in women.81 Therefore the relationship between
endothelial dysfunction and diabetes mellitus by gender remains unclear. In the current project,
we will examine this association using serum markers of endothelial dysfunction, including
sVCAM-1 and sICAM-1 in the Beaver Dam Eye Study, a large population-based cohort from
Wisconsin which included men and women in approximately equal number.
Previous studies exploring the relationship between endothelial dysfunction and
hypertension have found positive relationships in specialized populations such as pregnant
women,85 subjects with type 1 diabetes,86 and those with obstructive sleep apnea-hypopnea
syndrome.87 In the general population, only one previous cross-sectional study from China have
examined this association.88 Even though they reported a positive association between serum
sVCAM-1 and sICAM-1 levels and prevalent hypertension, due to the cross-sectional nature of
the study, the authors could not clarify whether adhesion molecules were elevated prior to
hypertension development or not. Therefore, a longitudinal cohort study exploring the
relationship between endothelial dysfunction in the general population is needed. In this context,
we will prospectively examine this association using markers of endothelial dysfunction in the
Beaver Dam Eye Study, a large, population-based, longitudinal cohort study from Wisconsin.
Previous cross-sectional studies exploring the relationship between endothelial
dysfunction and CKD found positive associations.67,69,70 However, endothelial function markers
are elevated as a consequence of CKD and dialysis.89,90 Therefore, a longitudinal study is
necessary to determine whether or not endothelial dysfunction preceded CKD onset. In the
6

current project, we will measure serum markers of endothelial dysfunction, including sVCAM-1
and sICAM-1, from stored serum specimens at the baseline examination and examine its
relationship to the risk of developing CKD over a 15 year follow-up period.
Previous studies have reported associations between markers of endothelial dysfunction
and cardiovascular mortality in ill populations, including those with kidney disease91, heart
failure92 and arthritis93. However, to our knowledge, no previous study has examined the
association between markers of endothelial dysfunction and cardiovascular mortality in the
general population. Therefore, we will use markers of endothelial dysfunction to explore
cardiovascular mortality in a non-clinical population.

1.4 SPECIFIC AIMS
The primary objectives of the current dissertation project are to determine the relations of
biomarkers of endothelial dysfunction to the long-term development of diabetes, hypertension,
chronic kidney disease and cardiovascular mortality in the general population. The proposal
takes advantage of the data on exposures and outcomes, including mortality, gathered over the
last 15 years, from a population-based cohort in Beaver Dam, Wisconsin. In the Beaver Dam Eye
Study (BEDS), we have data on glucose, glycosolated hemoglobin, and insulin injection use,
blood pressure and serum creatinine measured at the baseline, 5-year, 10-year and 15-year
follow-up examinations and mortality data which will enable us to define our primary outcomes,
diabetes, hypertension, CKD, cardiovascular (CVD) mortality and all-cause mortality. We also
have markers of endothelial dysfunction, including sVCAM-1 and sICAM-1 levels already
measured from the baseline blood samples of the cohort as part of a previous ancillary study. Our
study provides a unique opportunity to assess the temporal associations between new risk factors,
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such as markers of endothelial dysfunction, and the development of diabetes, hypertension, CKD
and mortality over a period of 15 years.
The specific aims of the current study are to determine the relation between biomarkers
of endothelial dysfunction (intercellular adhesion molecule 1 [ICAM-1] and vascular cell
adhesion molecule 1 [VCAM-1]) and the risk of developing

1) diabetes mellitus;
2) hypertension;
3) CKD; and
4) CVD mortality over a 15-year follow-up period.
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Chapter 2

Manuscript 1: The Association of Markers of Endothelial
Dysfunction and Incident Diabetes

9

2.1 INTRODUCTION
Endothelial dysfunction is a key pathophysiological process involved in the development of
cardiovascular disease.94 Endothelial dysfunction has also been shown to be related to insulin
resistance95, hyperglycemia59 and inflammation59 and therefore may have a role in the
development of diabetes mellitus. Also, in subjects with diabetes, endothelial dysfunction has
been reported to be predictive of subsequent complications, including nephropathy, retinopathy,
and cardiovascular disease.96 Soluble adhesion molecules, including serum levels of vascular
cell adhesion molecule-1 (sVCAM-1) and intercellular adhesion molecule -1 (sICAM-1) have
been used as markers of endothelial dysfunction in epidemiological studies.97 However, few
epidemiological studies have examined the relationship between soluble adhesion molecules and
incident diabetes and the results have not been consistent, as some studies reported a positive
association98-100 while others did not.84,101 Therefore, the independent relationship between
sVCAM-1 and sICAM-1 and incident diabetes in the general population remains unclear.
Therefore, we examined serum levels of sVCAM-1 and sICAM-1 in relationship to incident
diabetes in a population-based sample of adults from Wisconsin.
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2.2 METHODS
2.2.1Population
The current study is based on date from the Beaver Dam Eye study, a population-based
cohort study in Wisconsin originally aimed at studying age-related eye diseases. The methods
used to identify and describe the Beaver Dam population have appeared in previous
reports.102,103In brief, a private census of the population of Beaver Dam, Wisconsin, was
performed from September 1987 to May 1988 to identify all residents in the city or township of
Beaver Dam who were 43-84 years of age. Of the 5,924 eligible individuals (98% Caucasians),
4,926 (83.1%) participated in the baseline examination between March 1, 1988 and September
14, 1990. Comparisons between participants and nonparticipants at the time of the baseline
examination have appeared elsewhere.103
The baseline examination was followed by a 5-year follow-up examination from 1993 to
1995, a 10-year follow-up examination from 1998-2000, and a 15-year follow-up examination
from 2003-2005. Written informed consent was obtained from each subject at each examination.
The study was approved by the Human Subjects Committee of the University of Wisconsin
School of Medicine and Public Health, Madison, WI. Levels of sVCAM-1 and sICAM-1 were
measured in stored frozen serum on a random sample of the baseline cohort (n=1793) as part of
an ancillary study examining risk factors for kidney disease.
For the longitudinal analyses with sVCAM-1 and sICAM-1 as the main exposure, out of
1793 individuals with available sICAM-1 and sVCAM-1 measurements who participated in the
baseline and at least one follow-up examination, we excluded subjects with diabetes mellitus at
baseline (n=84), missing information on covariates included in the multivariable model (n=326)
and those who had a history of cardiovascular disease (n=264). This resulted in n=1119 diabetes11

free individuals with biomarker complete covariate information to form the at-risk study
population, among whom n=156 developed incident diabetes over the 15-year follow-up period.

2.2.2 Exposure ascertainment
The baseline and follow-up examinations included measurement of weight, height,
systolic and diastolic blood pressure by trained observers and administering a standardized
questionnaire that collected information regarding participants’ demographic characteristics,
details regarding cigarette smoking, alcohol intake, medical histories and medications taken,
including physician-diagnosed diabetes, hypertension or cardiovascular disease (CVD). Nonfasting blood specimens were obtained for measurement of plasma glucose, glycosylated
hemoglobin, serum total cholesterol and high density lipoprotein (HDL) cholesterol.
Age was defined as the participants’ age at the time of the baseline examination.
Education was categorized as less than high school, high school, or beyond high school. Body
mass index (BMI) was defined as participants’ weight in kilograms divided by their height in
meters squared. Hypertension was defined as a systolic blood pressure of 140 mmHg or higher,
and/or a diastolic blood pressure 90 mmHg or higher, and/or the combination of self-reported
hypertension diagnosis by a physician and use of antihypertensive medications.
At cohort examinations, blood samples were collected in three 10-mL liquid EDTA blood
tubes, placed on ice packs, stored in Styrofoam containers until they were centrifuged and
aliquoted for storage in freezers at –800C until the time of laboratory analysis. Quality control
samples were routinely frozen with study participant samples. Baseline frozen plasma samples
were randomly ordered (to further reduce systematic bias and inter assay variation) and thawed
and batch-analyzed for markers of endothelial function (sICAM-1, sVCAM-1).
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sICAM-1 (soluble intercellular adhesion molecule-1) was measured in plasma using the
quantitative sandwich enzyme technique of the enzyme-linked immunosorbent assay (ELISA)
Parameter kit from R & D Systems (Minneapolis, MN). The intensity of the color was measured
on a SpectraMax spectrophotometer (Molecular Devices, Sunnyvale, California). The interassay CV range was 6.0-10.1% for the plasma assay.
sVCAM-1 (soluble vascular cell adhesion molecule-1) was measured in plasma or serum
using the quantitative sandwich enzyme technique of the enzyme-linked immunosorbent assay
(ELISA) Parameter kit from R & D Systems (Minneapolis, MN). The intensity of the color was
measured on a SpectraMax spectrophotometer (Molecular Devices, Sunnyvale, California). The
inter-assay CV range was 8.9-10.2% for the plasma assay.

2.2.3 Outcome of Interest: Diabetes Mellitus
Persons were defined as having diabetes mellitus if were treated with insulin, oral
hypoglycemic agents, or were newly classified as having diabetes based on the glycosylated
hemoglobin value that was ≥ 6.5%, consistent with recent American Diabetes Association
guidelines104. Incident diabetes was defined as having newly diagnosed diabetes at the 5-, 10-, or
15-year follow-up examination among subjects free of diabetes at baseline.

2.2.4 Statistical methods
We were interested in the association between serum levels of sVCAM-1 and sICAM-1
and 15-year incident diabetes. We categorized VCAM and ICAM into tertiles for the main
analysis.
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We used chi-square test and analysis of variance to compare the relationship of selected baseline
characteristics to increasing categories of VCAM. We used multivariable Cox proportional
hazard regression models to determine the hazard ratio (HR) and 95 percent confidence interval
(CI) of 15-year incident diabetes, controlling simultaneously for potential confounders. We used
a multivariable-adjusted Cox proportional hazard regression model, adjusted for age, gender
(female, male), education (<high school, high school, >high school), smoking (never, former,
current), alcohol intake (never, former, current), BMI (kg/m2), hypertension (absent, present),
mean arterial blood pressure (mm Hg), serum total cholesterol (mg/dL) and high sensitivity Creactive protein (mg/dL). To examine the consistency of the association between sVCAM-1 and
sICAM-1 levels and incident diabetes, we performed subgroup analyses by gender (men,
women) and hypertensive status (yes, no).
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2.3 RESULTS
Among 1119 study participants included in the current analysis, there were 472 men and
647 women. Overall, 156 subjects (13.9%) developed diabetes over an average 15-year followup period, including 83 men and 73 women.
Table 2.1 presents the characteristics of the study population by increasing serum
sVCAM-1 levels at baseline. Those who had higher serum sVCAM-1 levels were more likely to
be older, educated below high school, never smokers and never or former drinkers. They were
also likely to have hypertension, lower total serum cholesterol levels and higher systolic blood
pressure.
Table 2.2 presents the association between increasing categories of serum sVCAM-1,
sICAM-1 and 15-year incident diabetes. The multivariable model for sVCAM-1 showed a
positive association between increasing serum sVCAM-1 levels and incident diabetesSimilarly,
the multivariable model for sICAM-1 showed a positive association between increasing serum
sICAM-1 levels and incident diabetes and the model evaluating linear trend in this association
was similarly just shy of statistical significance (p-trend=0.0623).
Table 2.3 presents the associations between increasing categories of serum sVCAM-1,
sICAM-1 and 15-year incident diabetes, stratified by gender. The multivariable model for
sVCAM-1 in women showed no association between increasing serum sVCAM-1 levels and
incident diabetes. In contrast, the multivariable model for sVCAM-1 in men showed a positive
association between increasing serum sVCAM-1 levels and incident diabetes. The model
evaluating the trend was statistically significant. Similarly, the multivariable model for sICAM-1
in women showed no association between increasing serum sICAM-1 levels and incident
diabetes. In contrast, the multivariable model for sICAM-1 in men showed a positive association
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between increasing sICAM-1 levels and incident diabetes. The model evaluating the trend was
statistically significant.
Table 2.4 presents the associations between increasing categories of serum sVCAM-1,
sICAM-1 and 15-year incident diabetes, stratified by hypertension status. The multivariable
model for sVCAM-1 in those without hypertension showed no association between increasing
serum sVCAM-1 levels and incident diabetes. In contrast, the multivariable model for sVCAM1in those with hypertension showed a positive association between increasing serum sVCAM-1
levels and incident diabetes.

The model evaluating the trend was just shy of statistical

significance. For sICAM-1, a similar pattern of association with incident diabetes was observed,
with no association among those without hypertension and a positive association among those
with hypertension. The model evaluating the trend was statistically significant.
Supplementary analyses were conducted to examine the association between serum
sVCAM-1 and sICAM-1 and incident diabetes, stratified by obesity status. We found that serum
sVCAM-1 and sICAM-1 were related to incident diabetes both among non-obese and obese
subjects. Compared to the lowest tertile of sVCAM-1 (referent), the multivariable odds ratio
(95% confidence interval) of incident diabetes was 1.45 (0.79, 2.66) in tertile 2 and 1.97 (1.063.67) in tertile 3 in obese subjects, and 1.01 (0.50, 2.01) in tertile 2 and 1.60 (0.88-2.90) in tertile
3 in non-obese subjects; p-interaction=0.1452. Results were similar for sICAM-1.
A second set of supplementary analyses were conducted to examine the association
between serum sVCAM-1 and sICAM-1 and incident diabetes, additionally adjusted for baseline
glycosolated hemoglobin in the multivariable model. Compared to the lowest tertile of sVCAM1 (referent), the multivariable odds ratio (95% confidence interval) of incident diabetes was 1.59
(1.03, 2.46) in tertile 2 and 1.67 (1.04-2.68) in tertile 3. Compared to the lowest tertile of
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sICAM-1 (referent), the multivariable odds ratio (95% confidence interval) of incident diabetes
was 1.29 (0.62, 2.68) in tertile 2 and 1.67 (1.00-2.79) in tertile 3.
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2.4 DISCUSSION
In a population-based sample of adults from Wisconsin, increasing serum levels of
sVCAM-1 and sICAM-1 were found to be positively associated with incident diabetes mellitus
in men, and in subjects with hypertension. In contrast, serum levels of sICAM-1 and sVCAM-1
were not found to be associated with diabetes mellitus in women, or in subjects without
hypertension. These contrasting associations were independent of smoking, alcohol intake,
education, hypertension, body mass index, total cholesterol and high sensitivity C - reactive
protein levels.
Serum levels of sICAM-1 and sVCAM-1 have been used in epidemiological research
before as reliable markers of endothelial dysfunction.97 Previous studies have reported that
markers of endothelial dysfunction are associated with increased risk of developing
cardiovascular disease.94 As diabetes is one of the strong risk factors for cardiovascular disease,
we examined if endothelial dysfunction markers are also related to diabetes mellitus.
Subsequently we found that markers of endothelial dysfunction are related to diabetes in men
and subjects with hypertension.
Our study results of an association between markers of endothelial dysfunction and
diabetes in men are consistent with a previous study by Thorand et al. showing serum sICAM-1
levels to be associated with increased risk of type 2 diabetes in men and not in women, with
hazard ratios of 1.32 and 1.03, respectively.84 Also, another study showed that when measuring
endothelial function as reactive hyperemia by peripheral arterial tonometry, endothelial
dysfunction was associated in adolescent males but not adolescent females.83 However, our
findings are inconsistent with previous research reporting sVCAM-1 and sICAM-1 to be
associated with diabetes in elderly women.98-100
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Several metabolic abnormalities associated with diabetes mellitus are thought to
contribute to endothelial dysfunction by disrupting mechanisms that regulate nitric oxide
synthesis, including conditions such as hyperglycemia, insulin resistance, excess free fatty acids
release and compensatory hyperinsulinemia.105 Therefore, it would be plausible for diabetes
mellitus to be associated with endothelial dysfunction.
The correct explanation for the lack of association between markers of endothelial
dysfunction and diabetes in women in the current study is not clear. One explanation may be that
female hormones are cardioprotective and therefore to some extent may mitigate any adverse
effect of endothelial dysfunction.106 There is a need for more studies in this topic to clarify the
modifying effect of female gender in the association between endothelial dysfunction and
diabetes.
In the current study we found that markers of endothelial dysfunction are associated with
diabetes among subjects with hypertension. It has been shown that endothelial dysfunction is one
of the hallmarks of hypertension107-109. Diabetes and hypertension are known to occur together
as part of the insulin resistance syndrome110 and as per the "common soil" hypothesis,111as they
may share common antecedents, such as adverse environmental conditions and less than optimal
nutrition. A corollary observation to our findings is that along with insulin resistance, endothelial
dysfunction may be one of the antecedent factors shared by hypertension and diabetes mellitus.
Strengths of this study include its population-based sample, high participation rate, use of
standardized protocols for exposure and outcome measurement and the availability of specific
markers of endothelial dysfunction, including sVCAM-1 and sICAM-1 levels. Also,
misclassification of diabetes status may have biased our results. A main study limitation is the
generalizability of our study to other populations.
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In conclusion, in a population-based sample of Wisconsin adults, we found that
increasing serum levels of sVCAM-1 and sICAM-1 levels were positively associated with 15year incident diabetes mellitus in men and in subjects with hypertension, independent of age
smoking status, alcohol intake, education, hypertension, BMI, total cholesterol levels and high
sensitivity c-reactive protein levels. In contrast, serum levels of sICAM-1 and sVCAM-1 were
not found to be associated with diabetes mellitus in women, or in subjects without hypertension.
This finding may suggest sVCAM-1 and sICAM-1 to be a novel risk factor risk factor in the
development of diabetes mellitus in men and in those with hypertension.
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2.5 TABLES
Table 2.1. Baseline characteristics by vascular cell adhesion molecule 1 (sVCAM -1) tertiles
Serum SVCAM-1 tertiles*
Characteristics
Tertile 1
Tertile 2
Tertile 3
p-value†
55.6 ± 0.51
58.40 ± 0.51
63.49 ± 0.51
< 0.0001
Age, years
Females, %
56.2%
58.2%
59.1%
0.7243
Education, %
< 0.0001
Below high school
14.6%
18.2%
27.8%
High school
47.3%
48.6%
43.6%
Above high school
38.1%
33.2%
28.6%
Smoking, %
0.1765
Never
43.5%
44.8%
49.6%
Former
32.4%
33.4%
33.3%
Current
24.1%
21.7%
17.1%
Alcohol intake categories, %
0.0062
Never
1.1%
3.0%
4.7%
Former
5.7%
7.3%
7.9%
Current drinker, <2 drinks/day
81.4%
81.3%
81.6%
Current drinker, ≥3 drinks/day
11.9%
8.4%
5.8%
28.4 ± 0.28
28.2 ± 0.28
28.9 ± 0.28
< 0.0001
Body mass index (BMI), kg/m2
241.5 ± 2.25
232.5 ± 2.26
226.1 ± 2.22
Serum total cholesterol mg/dL
< 0.0001
Hypertension, %
39.2%
38.6%
52.0%
0.0002
127.5 ± 0.98
127.7 ± 0.98
133.1 ± 0.97
Systolic blood pressure, mm Hg
< 0.0001
79.1 ± 0.54
77.3 ± 0.54
77.9 ± 0.53
Diastolic blood pressure, mm Hg
< 0.0001
*sVCAM-1 Tertiles : Tertile 1( ≤ 682.2 ng/ml) Tertile 2 (682.3-826.2 ng/ml) Tertile 3 (≥ 826.2 ng/ml)
†p-value estimated by analysis of variance or chi-square test as appropriate
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Table 2.2. Association between increasing serum levels of sVCAM-1 and sICAM-1 and incident diabetes
Serum sVCAM-1 tertiles*
(n=1119)
Tertile 1
Tertile 2
Tertile 3
p-trend

No. at
risk
370
368
381

Cases
42
60
54

Multivariable-adjusted
hazards ratio (95% confidence interval) ‡
1 (referent)
1.63 (1.07, 2.49)
1.46 (0.93, 2.31)
0.1187

Serum sICAM-1 tertiles †
(n=1119)
Tertile 1
370
43
1 (referent)
Tertile 2
368
48
1.09 (0.71, 1.69)
Tertile 3
381
65
1.52 (0.99, 2.33)
p-trend
0.0528
*sVCAM-1 Tertiles :Tertile 1( ≤ 682.2 ng/ml) Tertile 2 (682.3-826.2 ng/ml) Tertile 3 (≥ 826.2 ng/ml)
†sICAM-1 Tertiles : Tertile 1( ≤ 247.5 ng/ml) Tertile 2 (247.6-302.2 ng/ml) Tertile 3 (≥ 302.2 ng/ml)
‡Adjusted for age (years), sex (male, female), education categories (<high school, high school, >high school),
smoking (never, former, current), alcohol intake (never, former, current), body mass index (kg/m2), hypertension
(absent, present) and serum cholesterol (%), high sensitivity C reactive protein (mg/dl)
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Table 2.3. Association between increasing serum levels of sVCAM-1 and sICAM-1 and incident diabetes, by gender§
Women
Men
No. at risk
No. at risk
Multivariable-adjusted hazards
(diabetes
Multivariable-adjusted hazards ratio
(diabetes cases) ratio (95% confidence interval) ‡
cases)
(95% confidence interval) ‡
Serum sVCAM-1 tertiles*
(n=1119)
Tertile 1
208 (23)
1 (referent)
162 (19)
1 (referent)
Tertile 2
214 (26)
1.06 (0.58, 1.93)
154 (34)
2.17, (1.16, 4.05)
Tertile 3
225 (24)
0.90 (0.46, 1.77)
156 (30)
2.29 (1.18, 4.44)
p-trend
0.7413
0.0157
Serum sICAM-1 tertiles †
(n=1119)
Tertile 1
203 (22)
1 (referent)
167 (21)
1 (referent)
Tertile 2
219 (21)
0.80 (0.43, 1.52)
149 (27)
1.51 (0.82, 2.77)
Tertile 3
225 (30)
1.26 (0.69, 2.31)
156 (35)
1.88 (1.01, 3.48)
p-trend
0.4086
0.0451
*sVCAM-1 Tertiles :Tertile 1( ≤ 682.2 ng/ml) Tertile 2 (682.3-826.2 ng/ml) Tertile 3 (≥ 826.2 ng/ml)
†sICAM-1 Tertiles : Tertile 1( ≤ 247.5 ng/ml) Tertile 2 (247.6-302.2 ng/ml) Tertile 3 (≥ 302.2 ng/ml)
‡Adjusted for age (years), education categories (<high school, high school, >high school), smoking (never, former, current), alcohol intake (never,
former, current), body mass index (kg/m2), hypertension (absent, present) and serum cholesterol (%), high sensitivity C reactive protein (mg/dl)
§P-interaction for gender and sVCAM-1 = 0.1168
§P-interaction for gender and sICAM-1 = 0.2164
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Table 2.4. Association between increasing serum levels of sVCAM-1 and sICAM-1 and incident diabetes by hypertension status§
No Hypertension
Hypertension
No. at risk
Multivariable-adjusted hazards
No. at risk
Multivariable-adjusted hazards
(diabetes cases) ratio (95% confidence interval) ‡
(diabetes cases) ratio (95% confidence interval) ‡
Serum sVCAM-1 tertiles*
(n=1119)
Tertile 1
225 (25)
1 (referent)
145 (17)
1 (referent)
Tertile 2
226 (27)
1.08 (0.61, 1.93)
142 (33)
2.51 (1.32, 4.76)
Tertile 3
183 (21)
1.07 (0.56, 2.05)
198 (33)
2.03 (1.03, 3.99)
p-trend
0.8262
0.0556
Serum sICAM-1 tertiles †
(n=1119)
Tertile 1
225 (24)
1 (referent)
145 (19)
1 (referent)
Tertile 2
192 (21)
1.12 (0.60, 2.09)
176 (27)
1.17 (0.63, 2.18)
Tertile 3
217 (28)
1.08 (0.58, 2.01)
164 (37)
2.04 (1.11, 3.76)
p-trend
0.8022
0.0186
*sVCAM-1 Tertiles :Tertile 1( ≤ 682.2 ng/ml) Tertile 2 (682.3-826.2 ng/ml) Tertile 3 (≥ 826.2 ng/ml)
†sICAM-1 Tertiles : Tertile 1( ≤ 247.5 ng/ml) Tertile 2 (247.6-302.2 ng/ml) Tertile 3 (≥ 302.2 ng/ml)
‡Adjusted for age (years), sex (male, female), education categories (<high school, high school, >high school), smoking (never, former,
current), alcohol intake (never, former, current), body mass index (kg/m2),and serum cholesterol (%), high sensitivity C reactive protein (mg/dl)
§P-interaction for hypertension and sVCAM-1 = 0.3674
§P-interaction for hypertension and sICAM-1 = 0.1975
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Chapter 3
Manuscript 2: The Association of Markers of Endothelial
Dysfunction and Incident Hypertension
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3.1 INTRODUCTION
Endothelial dysfunction is a key pathophysiological process involved in the development of
cardiovascular disease.76 Endothelial dysfunction has also been shown to precede the
development of hypertension in animal models112,113. However the relationship between markers
of endothelial dysfunction and hypertension development in humans is not clear. Soluble
adhesion molecules, including serum levels of vascular cell adhesion molecule-1 (sVCAM-1)
and intercellular adhesion molecule -1 (sICAM-1) have been used as reliable markers of
endothelial dysfunction in epidemiological studies.114 In humans, markers of endothelial
dysfunction have been associated with hypertension in pregnant women,85 subjects with type 1
diabetes86 and those with obstructive sleep apnea-hypopnea syndrome.87 Also, in the general
population, Zhang et al88 showed that there was a positive association between sICAM-1 and Eselectin levels and hypertension in a cross-sectional survey from China. However, to our
knowledge, no epidemiological study has examined the relationship between soluble adhesion
molecules and the longitudinal risk of developing hypertension in the general population. In this
context, we examined the relation between serum levels of sVCAM-1 and sICAM-1 and the
cumulative incidence of hypertension over a period of 10 years in a population-based sample of
adults from Wisconsin.
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3.2 METHODS
3.2.1 Population
The current study is based on data from the Beaver Dam Eye study, a population-based
cohort study in Wisconsin. The methods used to identify and describe the Beaver Dam
population have appeared in previous reports.115,116 In brief, a private census of the population of
Beaver Dam, Wisconsin, was performed from September 1987 to May 1988 to identify all
residents in the city or township of Beaver Dam who were 43-84 years of age. Of the 5,924
eligible individuals (98% Caucasians), 4,926 (83.1%) participated in the baseline examination
between March 1, 1988 and September 14, 1990. Comparisons between participants and
nonparticipants at the time of the baseline examination have appeared elsewhere.116
The baseline examination was followed by a four follow-up examinations 5 year apart.
We limit our analyses to the first 10-years of follow-up. Written informed consent was obtained
from each subject at each examination. The study was approved by the Human Subjects
Committee of the University of Wisconsin School of Medicine and Public Health, Madison, WI.
Levels of sVCAM-1 and sICAM-1 were measured in stored frozen serum on a random sample of
the baseline cohort (n=1793) as part of an ancillary study examining risk factors for kidney
disease.
For the longitudinal analyses with sVCAM-1 and sICAM-1 as the main exposure, out of
1793 individuals with available sVCAM-1 and sICAM-1 measurements who participated in the
baseline and at least the 5- or 10-year follow-up examination, we excluded subjects with
prevalent hypertension at baseline (n=884) and missing information on covariates included in the
multivariable model (n=28) . This resulted in 881 participants without hypertension with
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complete biomarker and covariate information at baseline who were to form the at-risk
population.

3.2.2 Exposure ascertainment
The baseline and follow-up examinations included measurement of weight, height,
systolic and diastolic blood pressure by trained observers and administering a standardized
questionnaire that collected information regarding participants’ demographic characteristics,
details regarding cigarette smoking, alcohol intake, medical histories and medications taken,
including physician-diagnosed diabetes, hypertension or cardiovascular disease (CVD). Nonfasting blood specimens were obtained for measurement of plasma glucose, glycosylated
hemoglobin, serum total cholesterol and high density lipoprotein (HDL) cholesterol.
Age was defined as the participants’ age at the time of the baseline examination.
Education was categorized as less than high school, high school, or beyond high school. Body
mass index (BMI) was defined as participants’ weight in kilograms divided by their height in
meters squared. Diabetes mellitus was defined by use of using insulin, oral hypoglycemic
agents, or were newly classified as having diabetes based on the glycosylated hemoglobin value
that was ≥ 6.5%, consistent with recent American Diabetes Association guidelines.104 Chronic
kidney disease was defined as having chronic kidney disease were defined as having an
estimated glomerular filtration rate (GFR) of <60 ml/min per m2, estimated from serum
creatinine employing the re-expressed Modification of Diet in Renal Diseases (MDRD) study
equation.117
At cohort examinations, blood samples were collected in three 10-mL liquid EDTA blood
tubes, placed on ice packs, stored in Styrofoam containers until they were centrifuged and
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aliquoted for storage in freezers at –800C until the time of laboratory analysis. Quality control
samples were routinely frozen with study participant samples. Baseline frozen plasma samples
were randomly ordered (to further reduce systematic bias and inter assay variation) and thawed
and batch-analyzed for markers of endothelial function (sVCAM-1, sICAM-1).
sVCAM-1 (soluble vascular cell adhesion molecule-1) was measured in plasma or serum
using the quantitative sandwich enzyme technique of the enzyme-linked immunosorbent assay
(ELISA) Parameter kit from R & D Systems (Minneapolis, MN). The intensity of the color was
measured on a SpectraMax spectrophotometer (Molecular Devices, Sunnyvale, California). The
inter-assay CV range was 8.9-10.2% for the plasma assay.
sICAM-1 (soluble intercellular adhesion molecule-1) was measured in plasma using the
quantitative sandwich enzyme technique of the enzyme-linked immunosorbent assay (ELISA)
Parameter kit from R & D Systems (Minneapolis, MN). The intensity of the color was measured
on a SpectraMax spectrophotometer (Molecular Devices, Sunnyvale, California). The interassay CV range was 6.0-10.1% for the plasma assay.

3.2.3 Outcome of interest: Hypertension
Hypertension was defined as having a systolic blood pressure of 140 mmHg or higher,
and/or a diastolic blood pressure 90 mmHg or higher, and/or the combination of self-reported
hypertension diagnosis by a physician and use of antihypertensive medications. Incident
hypertension was defined as having newly diagnosed hypertension at the 5-, or 10 year follow-up
examination among subjects free of hypertension at baseline.
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3.2.4 Statistical methods
We examined the association between serum levels of sVCAM-1 and sICAM-1 and 10year incident hypertension. We categorized sVCAM-1and sICAM-1 into quartiles for the main
analysis. We also analyzed these markers as continuous variables, as per standard deviation
increase. We used chi-square test and analysis of variance to compare the relationship of selected
baseline characteristics by increasing categories of sVCAM-1 and sICAM-1. We used
multivariable Cox proportional hazard regression models to determine the hazard ratio (HR) and
95 percent confidence interval (CI) of 10-year incident hypertension, controlling simultaneously
for potential confounders, including age, gender (female, male), education (<high school, high
school, >high school), smoking (never, former, current), alcohol intake (never, former, current),
BMI (kg/m2), diabetes (absent, present), serum total cholesterol (mg/dL), chronic kidney disease
(absent, present) and self-reported history of cardiovascular disease (absent, present). To further
validate the associations between categories of sVCAM-1 and sICAM-1, we stratified by gender
(men, women), current smoking status (yes, no), obesity status (absent, present), diabetes status
(absent, present), glycosylated hemoglobin levels (%), and chronic kidney disease status (absent,
present). All analyses were performed in SAS version 9.2 (SAS Institute, Cary, NC).
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3.3 RESULTS
Among 881 study participants included in the current analysis, there were 390 men and
491 women. Overall, 257 subjects (29%) developed hypertension over an average 10-year
follow-up period, including 106 men and 151 women.
Table 3.1 presents the characteristics of the study population by increasing serum
sVCAM-1 levels at baseline. Those who had higher serum sVCAM-1 levels were more likely to
be older, never or former smokers. They were also likely to have higher systolic blood pressure
but lower diastolic blood.
Table 3.2 presents the association between increasing categories of serum sVCAM-1,
sICAM-1 and 10-year incident hypertension. The multivariable model for sVCAM-1 showed a
positive association between increasing serum sVCAM-1 levels and incident hypertension. The
model evaluating the trend was statistically significant (p-trend=0.0005). However, the
multivariable model for sICAM-1 showed no positive association between increasing serum
sICAM-1 levels and incident hypertension (p-trend=0.3203).
Table 3.3 presents the association between increasing categories of serum sVCAM-1 and
sICAM-1 and 10-year incident hypertension by gender. For sVCAM-1, the multivariable model
showed a positive association with incident hypertension in women as well as men. However, for
sVCAM-1 there was no association with incident hypertension in either sex.
Table 3.4 presents the associations between increasing categories of serum sVCAM-1,
sICAM-1 and incident hypertension, stratified by smoking, obesity, diabetes, and chronic kidney
disease status. Here also, generally in agreement with Table 2, the multivariable model for
sVCAM-1 showed a positive association with incident hypertension, but not for sICAM-1.
Formal statistical tests for interaction were not significant (all p-interactions>0.10).
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In a supplementary analysis when we adjusted for additional factors that may serve as
confounders, including the use of medications that may affect endothelial function such as statins
(current user, nonuser) and aspirin (current user, nonuser), and novel biomarkers such as high
sensitivity C-reactive protein level (mg/dL) and serum uric acid (mg/dL), the association
between increasing sVCAM-1 and sICAM-1 and hypertension remained materially the same. For
sVCAM1, compared to quartile 1 (referent), the multivariable HR (95% CI) of incident
hypertension was 1.39 (0.92, 2.10) in quartile 2, 1.75 (1.16, 2.64) in quartile 3, and 1.98 (1.39,
2.82); p-trend=0.0004. Also, for sICAM-1, compared to quartile 1 (referent), the multivariable
HR (95% CI) of incident hypertension was 1.29 (0.81, 2.05) in quartile 2, 1.09 (0.74, 1.61) in
quartile 3, and 1.18 (0.80, 1.74); p-trend=0.432.
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3.4 DISCUSSION
In a population-based sample of adults from Wisconsin, increasing serum levels of
sVCAM-1 were found to be positively associated with incident hypertension, independent of
smoking, alcohol intake, education, hypertension, body mass index, serum total cholesterol, and
chronic kidney disease. Serum sICAM-1, in contrast, was not found to be associated with
hypertension.
Serum levels of sVCAM-1 and sICAM-1 have been used previously in epidemiological
research as reliable markers of endothelial dysfunction.114 Previous studies have reported that
markers of endothelial dysfunction are associated with increased risk of developing
cardiovascular disease.76 As hypertension is a strong risk factor for cardiovascular disease, we
examined if endothelial dysfunction markers are also related to hypertension. Subsequently we
found that serum sVCAM-1 was positively related to incident hypertension in both men and
women.
The observed association between endothelial dysfunction and hypertension may be due
to endothelial damage and dysfunction impairing the vasodilator mechanism of endotheliumderived relaxing factor (nitric oxide), subsequently causing elevated blood pressure.63
Endothelial dysfunction may also be related to other mechanisms involved in the development of
hypertension, including insulin resistance64, systemic inflammation65 and hyperuricemia.66
However, in the current study, in a supplementary analysis, the association between sVCAM-1
and hypertension was found to be attenuated, but still present, after adjustment for markers of
inflammation and uric acid, suggesting that these mechanisms may only partially explain the
observed association.
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Our findings are consistent with one previous prospective epidemiological study
examining the relationship between biomarkers of endothelial dysfunction and hypertension in
those with type 1 diabetes86 and another cross-sectional study conducted in China.88 However,
another epidemiological study, the Multiethnic Study of Atherosclerosis (MESA), found no
association of endothelial dysfunction measured by brachial artery flow mediated-dilation with
incident hypertension.118 The reason for this discrepancy in findings with our study is not clear.
It is possible that serum levels of cellular adhesion molecules and brachial artery flow-mediated
dilatation may be measuring different aspects of endothelial function. For example, physiological
monitoring of flow-mediated dilatation is considered to be more dynamic and probably acutely
influenced by a subject's recent dietary119 or recent exposure to environmental pollution.120 Also,
studies in animals121 and humans122 have suggested that under different conditions (e.g.
prolonged hyperemic stimulus vs. transient increases in blood flow), flow mediated dilatation
may occur by mechanisms that are independent of endothelial nitric oxide production.123 Another
possibility is that there are potential racial/ethnic differences in the endothelial dysfunctionhypertension association as our study consisted of 99% whites whereas the MESA was a
multiethnic sample.
The reasons for the differing results that we observed for sVCAM-1 and sICAM-1 with
incident hypertension are not clear. It is possible that even though these adhesion molecules are
similar in structure and are members of the cytokine-inducible immunoglobulin gene
superfamily124. they have different functions. This notion is also supported by recent animal
studies that have shown that VCAM-1, and not ICAM-1, plays a major role in the initiation of
atherosclerosis125, and others that have reported differential expression patterns for these
adhesion molecules with VCAM-1 being expressed more in atherosclerotic lesions whereas
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ICAM-1 expression extending into uninvolved aorta and lesion protected regions126. However,
there is a need for more human studies to validate or refute our findings.
Strengths of this study include it being a large population-based cohort, high participation
rate, use of standardized protocols for exposure and outcome measurement and the availability of
specific markers of endothelial dysfunction, including sVCAM-1 and sICAM-1 levels. Our
results possess strong internal validity as we adjusted for known confounders and also the results
remained relatively consistent when we performed stratified analysis by confounders. Study
limitations include selective survival, the potential variability of endothelial dysfunction tests and
the limited generalizability of our study to other populations as this sample is a 99% white.
In conclusion, in a population-based sample of Wisconsin adults, we found that
increasing serum levels of sVCAM-1 were positively associated with 10-year incident
hypertension, independent of age smoking status, alcohol intake, education, hypertension, BMI,
total cholesterol levels, chronic kidney disease and history of cardiovascular disease. In contrast,
serum sICAM-1 was not found to be associated with hypertension.
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3.5 TABLES
Table 3.1. Baseline characteristics by soluble vascular cell adhesion molecule 1 (sVCAM -1) Quartile

Serum sVCAM-1 Quartile*
Quartile 4
Characteristics
Quartile 1
Quartile 2
Quartile 3
p-value†
54.4 ± 0.68
56.5 ± 0.68
59.5 ± 0.68
64.6 ± 0.68
< 0.0001
Age, years
53.6%
Females, %
58.4%
55.3%
55.7%
0.7924
Education, %
< 0.0001
31.8
Below high school
17.6%
12.3%
24.0%
43.6
High school
44.8%
54.8%
43.0%
24.6
Above high school
37.6%
32.9%
33.0%
Smoking, %
0.0040
43.6
Never
38.5%
41.6%
42.5%
42.3
Former
30.8%
33.3%
34.8%
14.1
Current
30.8%
25.1%
22.6%
Alcohol intake categories, %
0.0583
Never
0.9%
1.8%
1.8%
3.6%
Former
10.0%
8.2%
9.5%
11.8%
Current drinker, <2 drinks/day
79.2%
81.3%
84.6%
80.9%
Current drinker, ≥3 drinks/day
10.0%
8.7%
4.1%
3.6%
27.6 ± 0.35
27.8 ± 0.35
27.8 ± 0.35
27.8 ± 0.35
Body mass index (BMI), kg/m2
< 0.0001
236.2 ± 2.86
233.3 ± 2.87
227.1 ± 2.86
218.6 ±2.86
Serum total cholesterol, mg/dL
< 0.0001
6.8%
Diabetes mellitus, %
3.2%
1.8%
6.8%
0.0219
117.5 ± 0.76
118.6 ± 0.76
118.9 ± 0.76
120.7 ± 0.76
Systolic blood pressure, mm Hg
< 0.0001
74.1 ± 0.58
73.7 ± 0.58
73.7 ± 0.58
71.5 ± 0.58
Diastolic blood pressure, mm Hg
< 0.0001
*sVCAM-1 Quartile : Quartile 1( ≤ 641.0 ng/ml) Quartile 2 (641.2-759.1 ng/ml) Quartile 3 (759.2-887.6) Quartile 4 (≥887.6 ng/ml)
†p-value estimated by analysis of variance or chi-square test as appropriate
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Table 3.2. Association between increasing serum levels of sVCAM-1 and sICAM-1 and incident hypertension
Incident
No. at risk Hypertension
Multivariable-adjusted
Unadjusted hazards ratio (95%
Serum sVCAM-1 quartiles*
(n=881)
(n=257)
confidence interval)
hazards ratio (95% confidence interval) ‡
Quartile 1

221

46

1 (referent category)

1 (referent category)

Quartile 2

219

65

1.44 (0.95, 2.18)

1.47 (0.96, 2.26)

Quartile 3

221

72

1.81 (1.20, 2.74)

1.78 (1.17, 2.73)

Quartile 4

220

74

2.48 (1.63, 3.76)

2.14 (1.42, 3.23)

< 0.0001

0.0003

p-trend
Serum sICAM-1 quartiles†
Quartile 1

221

56

1 (referent category)

1 (referent category)

Quartile 2

219

66

1.33 (0.89, 1.98)

1.33 (0.88, 2.00)

Quartile 3

221

69

1.36 (0.91, 2.01)

1.15 (0.76, 1.74)

Quartile 4

220

66

1.58 (1.05, 2.36)

1.26 (0.85, 2.09)

0.0322

0.3603

p-trend

*sVCAM-1 Quartiles: Quartile 1 (0-641.0 (ng/ml)), Quartile 2 (641.1-759.1 ng/ml), Quartile 3 (759.2-887.6), Quartile 4 ( > 887.6 ng/ml)
†sICAM-1 Quartiles: Quartile 1 (0-233.9 (ng/ml)), Quartile 2 (234.0-277.8 ng/ml), Quartile 3 (277.9-334.2), Quartile 4 ( > 334.2 ng/ml)
‡Adjusted for age (years), gender (male, female) ,education categories (<high school, high school, >high school), smoking (never, former,
current), alcohol intake (never, former, current), body mass index (kg/m2), diabetes (absent, present), glycosylated hemoglobin (%),
chronic kidney disease (absent, present), history of cardiovascular disease (absent, present) and serum cholesterol (mg/dL)

37

Table 3.3. Association between increasing serum levels of sVCAM-1 and sICAM-1 and incident hypertension stratified by gender.
Men (n=390)
Multivariable-adjusted
hazards ratio (95% confidence interval) ‡

Women (n=491)
Multivariable-adjusted
hazards ratio (95% confidence interval) ‡

Quartile 1

1 (referent category)

1 (referent category)

Quartile 2

0.97 (0.48, 1.94)

1.95 (1.11, 3.40)

Quartile 3

1.69 (0.89, 3.21)

1.88 (1.05, 3.36)

Quartile 4

1.81 (1.01, 3.24)

2.86 (1.57, 5.22)

0.0440

0.0013

Quartile 1

1 (referent category)

1 (referent category)

Quartile 2

1.04 (0.55, 1.97)

1.59 (0.92, 2.77)

Quartile 3

0.84 (0.43, 1.65)

1.39 (0.83, 2.33)

Quartile 4

1.35 (0.71, 2.57)

1.28 (0.71, 2.31)

0.5100

0.4798

Serum sVCAM-1 quartiles*

p-trend
Serum sICAM-1 quartiles†

p-trend

* sVCAM-1: soluable vascular cell adhesion molecule-1; sVCAM Quartiles Quartile 1 (0-641.0 (ng/ml)), Quartile 2 (641.1-759.1 ng/ml),
Quartile 3 (759.2-887.6), Quartile 4 ( > 887.6 ng/ml)
†sICAM-1: soluable intercellular adhesión molecule-1; sICAM Quartiles: Quartile 1 (0-233.9 (ng/ml)), Quartile 2 (234.0-277.8 ng/ml),
Quartile 3 (277.9-334.2), Quartile 4 ( > 334.2 ng/ml)
‡Adjusted for age (years), education categories (<high school, high school, >high school), smoking (never, former, current), alcohol intake
(never, former, current), body mass index (kg/m2), diabetes (absent, present), glycosylated hemoglobin (%), chronic kidney disease (absent,
present), history of cardiovascular disease (absent, present) and serum cholesterol (mg/dL)
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Table 3.4. The association by sVCAM-1 and sICAM-1 and incident hypertension in selected subgroups
sICAM-1
sVCAM-1
The multivariable-adjusted hazards
The multivariable-adjusted hazards
ratio† (95% confidence interval) for
ratio† (95% confidence interval) for
one standard deviation increase‡
one standard deviation increase‡
No. at risk
Categories
Current Smoker
No

677

1.16 (0.96, 1.40)

0.98 (0.80, 1.19)

Yes

204

1.26 (0.78, 2.04)

1.21 (0.88, 1.66)

Absent

627

1.17 (0.93, 1.48)

1.05 (0.88, 1.25)

Present

254

1.23 (0.81, 1.87)

0.88 (0.63, 1.23)

Absent

840

1.27 (1.01, 1.57)

1.05 (0.90, 1.23)

Present

41

1.16 (0.67, 2.01)

0.28 (0.03, 2.46)

783

1.16 (0.95, 1.41)

1.12 (0.93, 1.35)

Obesity

Diabetes

Chronic kidney disease
Absent

Present
98
1.26 (0.70, 2.27)
0.55 (0.27, 1.12)
*All p-interactions > 0.10
† Adjusted for age (years), gender (male, female) ,education categories (<high school, high school, >high school),
smoking (never, former, current), alcohol intake (never, former, current), body mass index (kg/m2), diabetes (absent,
present), glycosylated hemoglobin (%), chronic kidney disease (absent, present), history of cardiovascular disease
(absent, present) and serum cholesterol (mg/dL); not adjusted for stratifying variable.
‡ one standard deviation sVCAM-1 = 323.0 units; one standard deviation of sICAM-1 = 99.2 units
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Chapter 4
Manuscript 3: The Association of Markers of Endothelial
Dysfunction and Incident Chronic Kidney Disease
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4.1 INTRODUCTION
Chronic kidney disease (CKD) is recognized as a risk factor for cardiovascular disease35,
and it also independently predicts cardiovascular mortality.36 Endothelial dysfunction is one of
the key pathophysiologic processes involved in the development of atherosclerotic vascular
disease.127 Binding and recruitment of circulating leukocytes to the vascular endothelium and
further migration into the subendothelial spaces are mediated through a diverse family of cellular
adhesion molecules that are expressed on the surface of vascular endothelial cells, including
sVCAM-1 and sICAM-1.128 Circulating levels of these adhesion molecules have been used as
markers of endothelial function in epidemiologic studies.129 Studies have shown that markers of
endothelial dysfunction, including sVCAM-1 and sICAM-1 are related to risk of developing
diabetes mellitus130 and hypertension,131 two of the well known risk factors of CKD.
Previous cross-sectional studies have shown that markers of endothelial function are
related to kidney disease132-134. However, since endothelial function markers are also elevated
secondary to CKD and dialysis,89,90,135 studies with longitudinal follow-up are required to
examine whether endothelial dysfunction precedes CKD onset. Therefore, we examined
biomarkers of endothelial dysfunction, including sVCAM-1 and sICAM-1 in relationship to the
15-year cumulative incidence of CKD in a population-based sample of adults from Wisconsin.
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4.2 METHODS
4.2.1 Population
The current study is based on data from the Beaver Dam Eye study, a population-based
cohort study in Wisconsin originally aimed at studying age-related eye diseases. The methods
used to identify and describe the Beaver Dam population have appeared in previous reports.
115,116

In brief, a private census of the population of Beaver Dam, Wisconsin, was performed from

September 1987 to May 1988 to identify all residents in the city or township of Beaver Dam who
were 43-84 years of age. Of the 5,924 eligible individuals (98% Caucasians), 4,926 (83.1%)
participated in the baseline examination between March 1, 1988 and September 14, 1990.
Comparisons between participants and nonparticipants at the time of the baseline examination
have appeared elsewhere116.
The baseline examination was followed by a 5-year follow-up examination from 1993 to
1995, a 10-year follow-up examination from 1998-2000, and a 15-year follow-up examination
from 2003-2005. Written informed consent was obtained from each subject at each examination.
The study was approved by the Human Subjects Committee of the University of Wisconsin
School of Medicine and Public Health, Madison, WI. Serum levels of sVCAM-1 and sICAM-1
were measured on a random sample of the baseline cohort (n=1793) as part of an ancillary study
examining risk factors for kidney disease.
For the longitudinal analyses with sVCAM-1 and sICAM-1 as the main exposure, out of
1793 individuals with available sVCAM-1 and sICAM-1 measurements who participated in the
baseline and at least one follow-up examination, we excluded subjects with CKD at baseline
(n=141), missing information on covariates included in the multivariable model (n=343) and
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those who had a history of cardiovascular disease (n=264). This resulted in n=1045 CKD-free
individuals with biomarker complete covariate information to form the at-risk study population.

4.2.2 Exposure ascertainment
The baseline and follow-up examinations included measurement of weight, height,
systolic and diastolic blood pressure by trained observers and administering standardized
questionnaire that collected information regarding participants’ demographic characteristics,
details regarding cigarette smoking, alcohol intake, medical histories and medications taken,
including physician-diagnosed diabetes, hypertension or cardiovascular disease (CVD). Nonfasting blood specimens were obtained for measurement of plasma glucose, glycosylated
hemoglobin, serum total cholesterol and high density lipoprotein (HDL) cholesterol.
Age was defined as the participants’ age at the time of the baseline examination.
Education was categorized as less than high school, high school, or beyond high school. Body
mass index (BMI) was defined as participants’ weight in kilograms divided by their height in
meters squared. Hypertension was defined as a systolic blood pressure of 140 mmHg or higher,
and/or a diastolic blood pressure 90 mmHg or higher, and/or the combination of self-reported
hypertension diagnosis by a physician and use of antihypertensive medications.
At cohort examinations, blood samples were collected in three 10-mL liquid EDTA blood
tubes, placed on ice packs, stored in Styrofoam containers until they were centrifuged and
aliquoted for storage in freezers at –800C until the time of laboratory analysis. Quality control
samples were routinely frozen with study participant samples. Baseline frozen plasma samples
were randomly ordered (to further reduce systematic bias and inter assay variation) and thawed
and batch-analyzed for markers of endothelial function (sVCAM-1, sICAM-1).
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sVCAM-1 (soluble vascular cell adhesion molecule-1) was measured in serum using the
quantitative sandwich enzyme technique of the enzyme-linked immunosorbent assay (ELISA)
Parameter kit from R & D Systems (Minneapolis, MN). The intensity of the color was measured
on a SpectraMax spectrophotometer (Molecular Devices, Sunnyvale, California). The interassay coefficient of variability (CV) range was 8.9-10.2%.
sICAM-1 (soluble intercellular adhesion molecule-1) was measured in serum using the
quantitative sandwich enzyme technique of the enzyme-linked immunosorbent assay (ELISA)
Parameter kit from R & D Systems (Minneapolis, MN). The intensity of the color was measured
on a SpectraMax spectrophotometer (Molecular Devices, Sunnyvale, California). The interassay CV range was 6.0-10.1%.

4.2.3 Outcome of Interest: Chronic Kidney Disease
Chronic kidney disease was defined as having an estimated glomerular filtration rate
(eGFR) of <60 ml/min per m2, using the re-expressed Modification of Diet in Renal Diseases
(MDRD) study equation 117 to estimate GFR for the main analysis and the CKD-EPI equation in
a supplementary analysis to verify the results.136 Incident CKD was defined as having newly
diagnosed CKD at the 5-, 10-, or 15-year follow-up examination among subjects free of CKD at
baseline.

4.2.4 Statistical methods
We were interested in the association between markers of endothelial dysfunction
(sVCAM-1 and sICAM-1 levels) and incident CKD. We categorized sVCAM-1 and sICAM-1
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into quartiles for the main analysis. We also analyzed these markers as continuous variables after
logarithmic transformation due to their skewed distribution.
We used chi-square test and analysis of variance to compare the relationship of selected
baseline characteristics to incident CKD status. We used multivariable Cox proportional hazard
regression models to determine the hazard ratio (HR) and 95 percent confidence interval (CI) of
15-year incident CKD, controlling simultaneously for potential confounders. We used two nested
Cox proportional hazard regression models: an unadjusted model and a multivariable-adjusted
model, additionally adjusted for age, gender (male, female), education (<high school, high
school, >high school), smoking (never, former, current), alcohol intake (never, former, current),
BMI (kg/m2), hypertension (absent, present), diabetes (absent, present) mean arterial blood
pressure (mm Hg), and serum total cholesterol (mg/dL). To further validate the associations
between increasing categories of sVCAM-1 and sICAM-1, we stratified by gender (men,
women) and hypertension status (hypertension, no hypertension).
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4.3 RESULTS
Among 1045 Wisconsin adults ≥43 years of age included in the current analysis, there
were 466 men and 579 women. Overall, 269 subjects developed CKD, including 107 men and
162 women.
Table 4.1 presents the characteristics of the study population by chronic disease status.
Those who had CKD were more likely to be older, female, have less than a high school
education, be never smokers, current or former drinkers, have hypertension and have higher
BMI, serum total cholesterol, and systolic and diastolic blood pressures.
Table 4.2 presents the associations between increasing categories of sVCAM-1, sICAM-1
and the 15-year cumulative incidence of CKD. The unadjusted-model for sVCAM-1 showed a
positive association between increasing levels of sVCAM-1 and incident CKD. However, the
multivariable-model for sVCAM-1 showed no association between increasing levels of sVCAM1 and incident CKD. Neither the unadjusted or multivariable models for sICAM-1 showed an
association between increasing levels of sICAM-1 and incident CKD.
Table 4.3 presents the associations between increasing categories of sVCAM-1 and
sICAM-1 and 15-year incident CKD by gender. For both men and women, the multivariable
model for sVCAM-1 as well as sICAM-1 showed no association between increasing levels of
these markers and incident CKD.
Table 4.4 presents the associations between increasing categories of sVCAM-1 and
sICAM-1 and 15-year incident CKD by hypertension status. For both without and with
hypertension, the multivariable model for sVCAM-1 as well as sICAM-1 showed no association
between increasing levels of these markers and incident CKD.

46

In a supplementary analysis, to examine the robustness of our findings, we analyzed the
associations between increasing categories of sVCAM-1, sICAM-1 and 15-year incident CKD,
employing the CKD-EPI equation instead of the MDRD equation; the results were found to be
essentially similar with no association between these markers and incident CKD. For sVCAM-1,
compared to quartile 1 (referent), the multivariable hazards ratio (95% confidence interval) of
incident CKD was 0.77 (0.46, 1.28) in quartile 2, 1.16 (0.73, 1.85) in quartile 3, and 0.90 (0.55,
1.45) in quartile 4; p-trend=0.9471. For ICAM-1, compared to quartile 1 (referent), the
multivariable hazards ratio (95% confidence interval) of incident CKD was 1.15 (0.71, 1.86) in
quartile 2, 1.43 (0.91, 2.27) in quartile 3, and 1.20 (0.73, 1.99) in quartile 4; p-trend=0.3082.

47

4.4 DISCUSSION
In a population-based sample, after adjusting for lifestyle and medical risk factors,
including gender, smoking status, alcohol intake, education, hypertension, body mass index and
total cholesterol increasing levels of sVCAM-1 and sICAM-1 were not associated with incident
CKD.
The vascular endothelium is involved in a variety of key processes important to human
health and disease, including control of coagulation137, fibrinolysis137,138 vascular tone137,139 and
growth139, immune response137,139, and oxidative stress138,140. Endothelial dysfunction has been
found to be closely related to insulin resistance141,142, elevated levels of inflammatory
markers141,143, impaired function of lipoprotein lipase (contributing to high triglycerides and low
HDL cholesterol levels)141,143, impaired nitric oxide release143 and endothelium dependent
vasodilation143. Endothelial dysfunction is also present in end-stage renal disesease134,144.
Biomarkers of endothelial dysfunction, including circulating adhesion molecules VCAM-1 and
ICAM-1 have been shown to be elevated even in less advanced stages of kidney disease132-134.
Several lines of recent evidence from animal studies support this hypothesis that
biomarkers of endothelial dysfunction may predict CKD. Janssen et al.145reported that ICAM-1
knockout mice developed significantly less severe experimentally induced nephrotoxic nephritis
and glomerular crescents compared to control mice. Similarly, Kawasaki et al. showed that
injection of antibodies against ICAM-1 prevented glomerular injury in experimental crescentic
glomerular nephritis146. To our knowledge, this is the first prospective study in humans to
examine the association between endothelial dysfunction and the development of renal disease
using circulating levels of cellular adhesion molecules. Circulating levels of cellular adhesion
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molecules are specific and valid markers of endothelial dysfunction and have been used
extensively in epidemiologic studies that utilized stored biospecimen130,131.
In the current study, we found that sVCAM-1 levels were initially moderately associated
with CKD in the unadjusted model but after adjusting for lifestyle and medical risk factors, the
association was no longer present. In contrast, sICAM-1 levels were not associated with CKD in
the unadjusted as well as the multivariable-adjusted model. The reasons for the observed
differential associations in CKD in the unadjusted model for sVCAM-1 and sICAM-1 are not
clear. Analogous to the recently reported differential associations of these adhesion molecules in
the brain microvasculature,147 it is possible that VCAM-1 and ICAM-1 may have differential
roles in leukocyte adhesion in renal microvessels also, with probably sVCAM-1 playing the
major role of leukocyte recruitment in kidneys.
This study has high internal validity as we adjusted for the main confounders and
performed stratified analyses by gender and hypertension status. Also, in contrast to Perticone,
et al148 who reported an association between endothelial dysfunction markers and CKD among
those with hypertension, the null association that we observed between markers of endothelial
dysfunction and CKD was consistently present in those with and without hypertension.
Strengths of this study include its population-based sample, high participation rate, use of
standardized protocols for exposure and outcome measurement and the availability of specific
markers of endothelial dysfunction, including sVCAM-1 and sICAM-1 levels. Our results of no
association between markers of endothelial dysfunction and incident CKD possess strong
internal validity as we adjusted for known confounders and also the results remained relatively
consistent when we performed stratified analysis by gender. A main study limitation is the
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generalizability of our study to other populations as this sample is a 99% white and is greater
than or equal to 43 years of age.
In conclusion, in a population-based sample of adults from Wisconsin, increasing levels
of sVCAM-1 and of sICAM-1 were not associated with incident CKD. Therefore, markers of
endothelial dysfunction such as sVCAM-1 and sICAM-1 may not be independently associated
with CKD.
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4.5. TABLES
Table 4.1. Baseline characteristics by chronic kidney disease (CKD) status
CKD status
Characteristics
No CKD
CKD
p-value†
57.3 ± 0.35
61.7 ± 0.59
<0.0001
Age, years
53.7%
60.2%
Females, %
0.0652
Education, %
0.0005
Below high school
16.8%
27.1%
High school
49.9%
40.2%
Above high school
33.4%
32.7%
Smoking, %
0.0314
Never
41.9%
50.2%
Former
36.7%
28.6%
Current
21.4%
21.2%
Alcohol intake categories, %
0.4570
Never
3.1%
2.6%
Former
7.0%
7.4%
Current drinker, <2 drinks/day
80.2%
83.3%
Current drinker, ≥3 drinks/day
9.8%
6.7%
2
28.6
±
0.20
29.2
± 0.35
Body mass index (BMI), kg/m
<0.0001
229.1 ± 1.19
238.1 ± 2.54
Serum total cholesterol, %
<0.0001
Hypertension, %
39.7%
54.6%
128.2 ± 0.67
133.4 ± 1.14
Systolic blood pressure, mm Hg
<0.0001
78.27 ± 0.37
78.94 ± 0.63
Diastolic blood pressure, mm Hg
<0.0001
†p-value estimated by analysis of variance or chi-square test as appropriate
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Table 4.2. Association between increasing serum levels of sVCAM-1 and sICAM-1 and incident CKD
Serum sVCAM-1 quartiles*
Cases
Unadjusted hazards ratio (95%
(n=1045)
No. at risk
(n=269)
confidence interval)

Multivariable-adjusted
hazards ratio (95% confidence interval)‡

Quartile 1

260

62

1 (referent category)

1 (referent category)

Quartile 2

262

52

0.87 (0.60, 1.25)

0.82 (0.55, 1.23)

Quartile 3

262

75

1.29 (0.92, 1.81)

1.15 (0.79, 1.67)

Quartile 4

261

80

1.53 (1.10, 2.13)

1.14 (0.77, 1.68)

0.0021

0.2662

2.23 (1.41, 3.53)

1.54 (0.91, 2.60)

p-trend
Log-transformed sVCAM-1
Serum sICAM-1 quartiles†
(n=1045)
Quartile 1

262

60

1 (referent category)

1 (referent category)

Quartile 2

260

69

1.16 (0.82, 1.64)

1.03 (0.70, 1.51)

Quartile 3

261

73

1.32 (0.94, 1.86)

1.05 (0.72, 1.54)

Quartile 4

262

67

1.18 (0.83, 1.67)

1.04 (0.69, 1.55)

0.2707

0.8466

1.54 (1.00, 2.38)

1.33 (0.79, 2.25)

p-trend
Log-tranformed sICAM-1

*sVCAM Quartiles: Quartile 1 (0-638.8 (ng/ml)), Quartile 2 (638.9-755.2 ng/ml), Quartile 3 (755.3-878.7), Quartile 4 ( > 878.7 ng/ml)
†sICAM-1: soluble intercellular adhesión molecule-1; sICAM Quartiles: Quartile 1 (0-234.2 (ng/ml)), Quartile 2 (234.3-278.4 ng/ml), Quartile 3 (278.5324.6), Quartile 4 ( > 342.6 ng/ml)
‡Adjusted for age (years), education categories (<high school, high school, >high school), smoking (never, former, current), alcohol intake (never, former,
current), body mass index (kg/m2), hypertension (absent, present) and serum cholesterol (%)
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Table 4.3. Association between increasing serum levels of sVCAM-1 and sICAM-1 and incident CKD stratified by gender
Men
Multivariable-adjusted
hazards ratio (95% confidence interval) ‡

Women
Multivariable-adjusted
hazards ratio (95% confidence interval) ‡

Quartile 1

1 (referent category)

1 (referent category)

Quartile 2

0.64 (0.35, 1.19)

0.97 (0.60, 1.56)

Quartile 3

1.33 (0.77, 2.30)

0.94 (0.59, 1.50)

Quartile 4

0.91 (0.49, 1.68)

1.20 (0.76, 1.89)

0.6041

0.4393

Quartile 1

1 (referent category)

1 (referent category)

Quartile 2

1.15 (0.65, 2.04)

0.96 (0.61, 1.50)

Quartile 3

1.28 (0.72, 2.27)

0.94 (0.61, 1.46)

Quartile 4

1.26 (0.69, 2.30)

0.90 (0.56, 1.45)

0.4112

0.6593

Serum sVCAM-1 quartiles* (n=1045)

p-trend
Serum sICAM-1 quartiles† (n=1045)

p-trend

* sVCAM-1: soluable vascular cell adhesion molecule-1; sVCAM Quartiles: Quartile 1 (0-638.8 (ng/ml)), Quartile 2 (638.9-755.2 ng/ml),
Quartile 3 (755.3-878.7), Quartile 4 ( > 878.7 ng/ml)
†sICAM-1: soluable intercellular adhesión molecule-1; sICAM Quartiles: Quartile 1 (0-234.2 (ng/ml)), Quartile 2 (234.3-278.4 ng/ml),
Quartile 3 (278.5-324.6), Quartile 4 ( > 342.6 ng/ml)
‡Adjusted for age (years), education categories (<high school, high school, >high school), smoking (never, former, current), alcohol intake
(never, former, current), body mass index (kg/m2), hypertension (absent, present) and serum cholesterol (%)
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Table 4. 4. Association between increasing serum levels of sVCAM-1 and sICAM-1 and incident CKD stratified by hypertension status
No Hypertension
Hypertension
(n=590)
(n=455)
Multivariable-adjusted
Multivariable-adjusted
hazards ratio (95% confidence interval) ‡
hazards ratio (95% confidence interval) ‡
Serum sVCAM-1 quartiles*(n=1045)
Quartile 1

1 (referent category)

1 (referent category)

Quartile 2

0.73 (0.41, 1.30)

0.92 (0.52, 1.62)

Quartile 3

1.15 (0.68, 1.96)

1.12 (0.64, 1.94)

Quartile 4

1.10 (0.62, 1.95)

1.83 (0.69, 2.04)

0.4589

0.4198

Quartile 1

1 (referent category)

1 (referent category)

Quartile 2

1.39 (0.81, 2.39)

0.79 (0.46, 1.36)

Quartile 3

0.82 (0.45, 1.45)

1.21 (0.72, 2.03)

Quartile 4

1.29 (0.72, 2.32)

0.85 (0.48, 1.51)

0.7463

0.9415

p-trend
Serum sICAM-1 quartiles† (n=1045)

p-trend

* sVCAM-1: soluable vascular cell adhesion molecule-1; sVCAM Quartiles: Quartile 1 (0-638.8 (ng/ml)), Quartile 2 (638.9-755.2 ng/ml),
Quartile 3 (755.3-878.7), Quartile 4 ( > 878.7 ng/ml)
†sICAM-1: soluable intercellular adhesión molecule-1; sICAM Quartiles: Quartile 1 (0-234.2 (ng/ml)), Quartile 2 (234.3-278.4 ng/ml),
Quartile 3 (278.5-324.6), Quartile 4 ( > 342.6 ng/ml)
‡Adjusted for age (years), education categories (<high school, high school, >high school), smoking (never, former, current), alcohol intake
(never, former, current), body mass index (kg/m2), and serum cholesterol (%)
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Chapter 5
Manuscript 4: The Association of Markers of Endothelial
Dysfunction and Cardiovascular Mortality
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5.1 INTRODUCTION
Cardiovascular disease is the leading cause of mortality in the United States.149
Endothelial dysfunction is a key pathophysiological process involved in the development of
cardiovascular disease.76 Soluble adhesion molecules, including serum levels of soluble vascular
cell adhesion molecule-1 (sVCAM) and intercellular adhesion molecule -1 (sICAM) have been
used as reliable markers of endothelial dysfunction in epidemiological studies.150 sVCAM-1 and
sICAM-1 levels have shown to be associated with cardiovascular disease in the general
population114,151 and have also been shown to be associated with cardiovascular mortality in
subjects undergoing hemodialysis91, and those with coronary heart disease92 and rheumatoid
arthritis93. However, to our knowledge, no epidemiological study has examined the putative
relationship between soluble adhesion molecules and cardiovascular mortality in the general
population. Therefore, we examined serum levels of sVCAM-1 and sICAM-1 in relationship to
cardiovascular mortality in a population-based sample of adults from Wisconsin.
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5.2 METHODS
5.2.1 Population
The current study is based on data from the Beaver Dam Eye study, a population-based
cohort study in Wisconsin originally aimed at studying age-related eye diseases. The methods
used to identify and describe the Beaver Dam population have appeared in previous reports.152,153
In brief, a private census of the population of Beaver Dam, Wisconsin, was performed from
September 1987 to May 1988 to identify all residents in the city or township of Beaver Dam who
were 43-84 years of age. Of the 5,924 eligible individuals (98% Caucasians), 4,926 (83.1%)
participated in the baseline examination between March 1, 1988 and September 14, 1990.
Comparisons between participants and nonparticipants at the time of the baseline examination
have appeared elsewhere153.
The baseline examination was followed by four follow-up examinations every 5 years.
Written informed consent was obtained from each subject at each examination. The study was
approved by the Human Subjects Committee of the University of Wisconsin School of Medicine
and Public Health, Madison, WI. Serum levels of sVCAM-1 and sICAM -1 were measured on a
random sample of the baseline cohort (n=1793) as part of an ancillary study examining risk
factors for kidney disease.
For the longitudinal analyses with sVCAM-1 and sICAM-1 as the main exposure, out of
1793 individuals with available sVCAM-1 and sICAM-1 measurements, we excluded subjects
with missing information on covariates included in the multivariable model (n=38) and those
who had a history of prevalent cardiovascular disease (n=247). This resulted in n=1508
cardiovascular disease-free individuals with complete covariate information to form the at-risk
study population.
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5.2.2 Exposure ascertainment
The baseline and follow-up examinations included measurement of weight, height,
systolic and diastolic blood pressure by trained observers and administering a standardized
questionnaire that collected information regarding participants’ demographic characteristics,
details regarding cigarette smoking, alcohol intake, medical histories and medications taken,
including physician-diagnosed diabetes, hypertension or cardiovascular disease (CVD). Nonfasting blood specimens were obtained for measurement of plasma glucose, glycosylated
hemoglobin, serum total cholesterol and high density lipoprotein (HDL) cholesterol.
Age was defined as the participants’ age at the time of the baseline examination.
Education was categorized as less than high school, high school, or beyond high school. Body
mass index (BMI) was defined as participants’ weight in kilograms divided by their height in
meters squared. Hypertension was defined as a systolic blood pressure of 140 mmHg or higher,
and/or a diastolic blood pressure 90 mmHg or higher, and/or the combination of self-reported
hypertension diagnosis by a physician and use of antihypertensive medications. Diabetes was
defined as being treated with insulin, oral hypoglycemic agents, or were newly classified as
having diabetes based on the glycosylated hemoglobin value that was ≥ 6.5%, consistent with
recent American Diabetes Association guidelines104 Chronic kidney disease was defined as
having chronic kidney disease were defined as having an estimated glomerular filtration rate
(GFR) of <60 ml/min per m2, estimated from serum creatinine employing the re-expressed
Modification of Diet in Renal Diseases (MDRD) study equation.117
At cohort examinations, blood samples were collected in three 10-mL liquid EDTA blood
tubes, placed on ice packs, stored in Styrofoam containers until they were centrifuged and
aliquoted for storage in freezers at –800C until the time of laboratory analysis. Quality control
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samples were routinely frozen with study participant samples. Baseline frozen plasma samples
were randomly ordered (to further reduce systematic bias and inter assay variation) and thawed
and batch-analyzed for markers of endothelial function (sVCAM-1, sICAM-1).
sVCAM-1 was measured in plasma or serum using the quantitative sandwich enzyme
technique of the enzyme-linked immunosorbent assay (ELISA) Parameter kit from R & D
Systems (Minneapolis, MN). The intensity of the color was measured on a SpectraMax
spectrophotometer (Molecular Devices, Sunnyvale, California). The inter-assay CV range was
8.9-10.2%..
sICAM-1 (was measured in plasma using the quantitative sandwich enzyme technique of
the enzyme-linked immunosorbent assay (ELISA) Parameter kit from R & D Systems
(Minneapolis, MN). The intensity of the color was measured on a SpectraMax
spectrophotometer (Molecular Devices, Sunnyvale, California). The inter-assay CV range was
6.0-10.1%.

5.2.3 Outcome of Interest: Cardiovascular Mortality
We ascertained mortality between the baseline examination and December 31, 2002.
Mortality surveillance of the cohort consisted of reviews of daily newspaper obituaries, regular
contact with study participants and their relatives, designated contact persons, or physicians.
Deaths were confirmed with death certificate data from annual requests made to the Wisconsin
Center for Health Statistics, Section of Vital Statistics. The names of persons who have moved
out of Wisconsin and those who had been lost to follow-up or were suspected to have died were
submitted for matching against Wisconsin death records and the National Death Index. For each
match made, a copy of the death certificate was secured from the appropriate state. Only deaths
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that have been confirmed by death certificates were included in the definition of mortality. Death
certificates were collected and coded by trained nosologists using the International Classification
of Diseases, Ninth Revision (ICD-9). We have estimated that all the deaths in the cohort have
been identified by our surveillance methods. Cardiovascular mortality was identified using ICD
9 codes 401-459, including death due to coronary heart disease and stroke as the underlying
cause of death.

5.2.4 Statistical methods
We were interested in the association between serum levels of sVCAM-1 and sICAM-1
and cardiovascular mortality. We categorized sVCAM-1 and sICAM-1 into quartiles for the
main analysis. We also analyzed these markers as continuous variables after logarithmic
transformation due to their skewed distribution.
We used chi-square test and analysis of variance to compare the relationship of selected
baseline characteristics to increasing categories of sVCAM-1. We used multivariable Cox
proportional hazard regression models to determine the hazard ratio (HR) and 95 percent
confidence interval (CI) of 15-year cardiovascular mortality, controlling simultaneously for
potential confounders. We used two nested Cox proportional hazard regression models: an
unadjusted model and a multivariable-adjusted model, adjusted for age (years), education
categories (<high school, high school, >high school), smoking (never, former, current), alcohol
intake (never, former, current), body mass index (kg/m2), hypertension (absent, present), diabetes
(absent, present), serum cholesterol (%) and chronic kidney disease (yes, no). To examine the
consistency of the association between sVCAM-1 and sICAM-1 levels and cardiovascular
mortality, we performed subgroup analyses by gender (men, women), diabetes mellitus (absent,
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present), hypertension (absent, present) and chronic kidney disease (absent, present). Finally, we
evaluated effect modification by including cross-product multiplicative interaction terms in
regression models (alpha=0.l0 for testing interaction).
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5.3 RESULTS
Among 1508 study participants included in the current analysis, there were 639 men and
869 women. Overall, 212 subjects (14%) died of cardiovascular causes, including 96 men and
116 women.
Table 5.1 presents the characteristics of the study population by increasing serum
sVCAM-1 levels at baseline. Those who had higher serum sVCAM-1 levels were more likely to
be older, educated below high school, never smokers, never drinkers, have lower cholesterol
levels and diastolic blood pressures.
Table 5.2 presents the association between increasing categories of serum sVCAM-1,
sICAM-1 and cardiovascular mortality. The multivariable model for sVCAM-1 showed a
positive association between increasing serum sVCAM-1 levels and cardiovascular mortality,
although the model evaluating linear trend in this association was just shy of statistical
significance (p-trend=0.0904). The multivariable model for sICAM-1 showed a positive
association between increasing serum sICAM-1 levels and cardiovascular mortality and the
model evaluating linear trend in this association was statistically significant (p-trend=0.0097).
Table 5.3 presents the associations between increasing categories of serum sVCAM-1,
sICAM-1 and cardiovascular mortality, stratified by gender, diabetes, hypertension, chronic
kidney disease and BMI status. The multivariable model for sVCAM-1 showed a stronger
association with cardiovascular mortality in women, those with diabetes, hypertension, chronic
kidney disease and those with normal BMI. The multivariable model for sICAM-1 showed a
stronger association with cardiovascular mortality in women, in those without diabetes and
hypertension and in those with chronic kidney disease and normal BMI. Formal statistical tests
for interaction were not significant (all p-interactions>0.10).
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Supplementary analyses that additionally adjusted for high sensitivity c-reactive in the
multivariable model as a marker of inflammation did not alter the magnitude of results.
Compared to the lowest quartiles of sVCAM-1 (referent) and sICAM-1 (referent), the
multivariable odds ratio (95% confidence interval) of cardiovascular mortality for sVCAM-1
quartiles 1-4 respectively were 1.34 (0.80, 2.24), 1.26 (0.77, 2.08), and 1.53 (0.94, 2.51)) and for
sICAM-1 quartiles 1-4 respectively were 1.39 (0.89, 2.17), 1.42 (0.92, 2.20) and 1.73 (1.13, 2.76).
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5.4 DISUCSSION
In a population-based sample of adults from Wisconsin, increasing serum levels of
sVCAM-1 and sICAM-1 were found to be positively associated with cardiovascular mortality.
These associations were independent of age, gender smoking, alcohol intake, education,
hypertension, diabetes, chronic kidney disease, body mass index and total cholesterol. In
subgroup analyses, the association between sVCAM-1 and sICAM-1 levels and cardiovascular
mortality appeared to be relatively consistently present among those with and without diabetes,
hypertension, chronic kidney disease and obesity.
Serum levels of sICAM-1 and sVCAM-1 have been used in epidemiological research
before as reliable markers of endothelial dysfunction.150 Previous studies have reported that
markers of endothelial dysfunction are associated with increased risk cardiovascular
disease76,114,151 and cardiovascular mortality in ill subpopulations.91-93 However, since these
endothelial dysfunction markers are also known to be elevated secondary to these chronic
diseases (or as a result of treatments for these diseases, such as hemodialysis for kidney disease),
results from such studies of patient cohorts may not reflect disease processes occurring in the
general population. In the current study, we examined, to our knowledge for the first time, the
association between increasing levels of markers of endothelial dysfunction in serum and their
relationship to cardiovascular mortality in a general population sample. Subsequently, we found
that markers of endothelial dysfunction are positively related to cardiovascular mortality. This
finding is consistent with a previous report of an overall association of markers of endothelial
dysfunction and incident cardiovascular disease in the Atherosclerosis Risk in Communities
Study.114
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Because there are several cardiovascular risk factors that are associated with an increase
in endothelial dysfunction, including gender154,155, diabetes,156,157 hypertension,157,158chronic
kidney disease159,160 and obesity161,162, we adjusted and stratified by these risk factors to test the
independent association between these markers of endothelial dysfunction and cardiovascular
mortality. We found that the association between endothelial dysfunction and cardiovascular
mortality was attenuated, but still present, even after multivariable adjustment for confounders.
Also, there was no statistically significant difference in the association of markers of endothelial
dysfunction to cardiovascular mortality in subgroup analyses by gender, diabetes, hypertension,
chronic kidney disease and BMI.
The intact, healthy endothelium secretes various cardio-protective substances including
nitric oxide, which diffuses to surrounding tissues and cells, relaxing smooth-muscle cells and
preventing platelet adhesion and aggregation, preventing expression of adhesion molecules,
leukocyte adhesion and migration into the arterial wall and arterial smooth muscle cell
proliferation77. Conversely, early stages of endothelial dysfunction is characterized by increased
formation of reactive oxygen species and increased expression of adhesion molecules such as
sVCAM-1 and sICAM-1, which can react with NO forming peroxynitrate78, reducing NO
bioavailability, which over the long run may be involved in increased risk of cardiovascular
disease79. Results from our study, which show a positive association between increased
circulating levels of endothelial adhesion molecules and cardiovascular mortality in a general
population sample, are therefore consistent with these proposed biological mechanisms and
indirectly suggest that there may be a role for treating endothelial dysfunction to prevent
cardiovascular mortality.
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Strengths of this study include its population-based sample, high participation rate, use of
standardized protocols for exposure and outcome measurement, complete mortality surveillance
and the availability of specific markers of endothelial dysfunction, including sVCAM-1 and
sICAM-1 levels. Also, misclassification of cardiovascular mortality may have biased our results.
Study limitation include selective survival, high variability and the generalizability of our study
to other populations as this sample is a 99% white and is greater than or equal to 43 years of age.
In conclusion, in a population-based sample of Wisconsin adults, we found that
increasing serum levels of sVCAM-1 and sICAM-1 levels were positively associated with
cardiovascular mortality, independent of age smoking status, alcohol intake, education,
hypertension, diabetes, chronic kidney disease, BMI, and total cholesterol levels.
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5.5 TABLES
Table 5.1. Baseline characteristics by vascular cell adhesion molecule 1 (sVCAM -1) quartiles
Serum sVCAM-1 quartiles*
Characteristics
Quartile 1
Quartile 2
Quartile 3
Quartile 4
p-value†
55.5 ± 0.52
58.7 ± 0.52
61.0 ± 0.52
67.0 ± 0.52
<0.0001
Age, years
Females, %
55.2%
54.6%
57.8%
62.9%
0.0878
Education, %
Below high school
16.7%
21.2%
24.4%
37.9%
<0.0001
High school
46.4%
47.8%
47.8%
39.0%
Above high school
36.9%
31.0%
27.8%
23.1%
Smoking, %
0.0003
Never
41.4%
43.2%
44.8%
54.4%
Former
32.1%
34.0%
34.5%
32.3%
Current
26.5%
22.8%
20.7%
13.3%
Alcohol intake categories, %
<0.0001
Never
1.0%
2.1%
3.5%
5.8%
Former
8.8%
8.7%
9.8%
13.3%
Current drinker, <2 drinks/day
77.2%
79.6%
80.3%
76.4%
Current drinker, ≥3 drinks/day
13.0%
9.6%
6.4%
4.5%
28.7 ± 0.29
28.3 ± 0.29
29.2 ± 0.29
29.1 ± 0.29
Body mass index (BMI), kg/m2
<0.0001
242.6 ± 2.26
235.6 ± 2.26
230.2 ± 2.26
226.9 ± 2.26
Serum total cholesterol, %
<0.0001
Hypertension, %
39.8%
46.4%
43.5%
61.5%
<0.0001
128.4 ± 1.01
130.2 ± 1.01
130.0 ± 1.01
137.7 ±1.01
Systolic blood pressure, mm Hg
<0.0001
78.7
±
0.56
78.1
±
0.56
77.4
±
0.56
77.2
±
0.56
Diastolic blood pressure, mm Hg
<0.0001
*sVCAM-1 Quartiles: Quartile 1 (0-651.6 (ng/ml)), Quartile 2 (651.7-768.2 ng/ml), Quartile 3 (768.3-918.8), Quartile 4 ( >918.8 ng/ml)
†p-value estimated by analysis of variance or chi-square test as appropriate
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Table 5.2. Association between increasing serum levels of sVCAM-1 and sICAM-1 and cardiovascular mortality
Mortality
Serum sVCAM-1 quartiles*
Multivariable-adjusted
Unadjusted hazards ratio (95%
cases
(n=1508)
No. at risk
(n=212)
confidence interval)
hazards ratio (95% confidence interval) ‡
Quartile 1

377

24

1 (referent category)

1 (referent category)

Quartile 2

377

39

1.68 (1.01, 2.79)

1.31 (0.78, 2.19)

Quartile 3

377

54

2.40 (1.48, 3.88)

1.22 (0.74, 2.01)

Quartile 4

377

95

4.90 (3.07, 7.52)

1.56 (0.95, 2.54)

< 0.0001

0.0904

p-trend
Serum sICAM-1 quartiles†
(n=1504)
Quartile 1

377

31

1 (referent category)

1 (referent category)

Quartile 2

378

52

1.69 (1.09, 2.63)

1.45 (0.93, 2.26)

Quartile 3

372

59

2.01 (1.31, 3.10)

1.47 (0.95, 2.27)

Quartile 4

377

69

2.47 (1.62, 3.76)

1.79 (1.17, 2.76)

< 0.0001

0.0097

p-trend

*sVCAM-1 Quartiles: Quartile 1 (0-651.6 (ng/ml)), Quartile 2 (651.7-768.2 ng/ml), Quartile 3 (768.3-918.8), Quartile 4 ( >918.8 ng/ml)
†sICAM-1 Quartiles: Quartile 1 (0-237.2 (ng/ml)), Quartile 2 (237.3-281.2 ng/ml), Quartile 3 (281.3-330.8), Quartile 4 ( > 330.8 ng/ml)
‡Adjusted for age (years), education categories (<high school, high school, >high school), smoking (never, former, current), alcohol intake
(never, former, current), body mass index (kg/m2), hypertension (absent, present), diabetes (absent, present), serum cholesterol (%),
chronic kidney disease (yes, no)
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Table 5.3. Association by sICAM-1 and sVCAM-1 and cardiovascular mortality in selected subgroups*
sICAM-1
sVCAM-1
The multivariable-adjusted hazards ratio† (95%
The multivariable-adjusted hazards ratio† (95%
confidence interval) for one standards deviation
confidence interval) for one standards deviation
Sample
increase‡
increase‡
size
Categories
Gender
Female

869

1.51 (1.18, 1.95)

1.54 (1.18, 2.01)

Men

639

1.25 (1.00, 1.56)

1.13 (0.92, 1.35)

Normal BMI

361

1.59 (1.11, 2.27)

1.60 (1.09, 2.32)

Overweight/Obese

1144

1.34 (1.08, 1.67)

1.14 (0.96, 1.36)

Absent

1020

1.34 (1.10, 1.62)

1.36 (1.13, 1.64)

Present

488

1.68 (1.09, 2.60)

1.21 (0.93, 1.58)

Absent

560

1.28 (0.95, 1.73)

1.88 (1.25, 2.83)

Present

948

1.39 (1.11, 1.73)

1.08 (0.90, 1.30)

1240

1.35 (1.06, 1.70)

1.18 (0.98, 1.43)

Body Mass Index

Diabetes mellitus

Hypertension

Chronic kidney disease
Absent

Present
268
1.41 (1.12, 1.96)
1.37 (1.08, 1.75)
*All p-interactions > 0.10
† Adjusted for age (years), gender (male, female), education categories (<high school, high school, >high school), smoking (never, former,
current), alcohol intake (never, former, current), body mass index (kg/m2), hypertension (absent, present), diabetes (absent, present), serum
cholesterol (%), chronic kidney disease (yes, no)
‡ one standard deviation sVCAM-1 = 288.4 units; one standard deviation of sICAM-1 = 98.5 units
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Chapter 6
Discussion
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6.1 SUMMARY OF KEY FINDINGS
In an attempt to resolve the current gaps in literature (as mentioned in the Introduction
section), we conducted four related studies in a large population-based cohort study in Beaver
Dam, Wisconsin, to examine the role of serum markers of endothelial dysfunction on various
common metabolic and cardiovascular outcomes in humans, including diabetes mellitus,
hypertension, CKD, and cardiovascular mortality. We found that markers of endothelial
dysfunction, including serum sVCAM-1 and sICAM-1, were positively associated with the risk
of developing diabetes, hypertension, and cardiovascular mortality, but not with CKD (see a
summary of these findings in Table 6.1.). Further, in subgroup analyses, we found that the
association between these endothelial dysfunction markers and diabetes mellitus was present
mainly in men, but not women. All other associations were present similarly in men and women.
Based on these findings, we propose a conceptual model that markers of endothelial dysfunction
are related to cardiovascular mortality probably through its relation to diabetes mellitus and
hypertension, but not to CKD (see Figure 6.1.).

6.2 ENDOTHELIAL DYSFUNCTION AND DIABETES MELLITUS (MANUSCRIPT
1/CHAPTER 2)
The findings from our first manuscript of an association between sVCAM-1 and sICAM1 and diabetes mellitus in men are consistent with a previous study by Thorand et al. showing
serum endothelial dysfunction marker levels to be associated with increased risk of type 2
diabetes in men and not in women.84 Also, another study showed that when measuring
endothelial function as reactive hyperemia by peripheral arterial tonometry, endothelial
dysfunction was associated with diabetes and hyperglycemia in adolescent males but not
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adolescent females.83 It is biologically plausible that endothelial dysfunction is related to incident
diabetes mellitus through its relation to mechanisms such as hyperglycemia, insulin resistance,
excess free fatty acids release and compensatory hyperinsulinemia.105 Similarly, several
plausible mechanisms can be postulated to explain the lack of association between endothelial
dysfunction and diabetes mellitus in women in the current study, including that female hormones
are cardioprotective and therefore to some extent may mitigate any adverse effect of endothelial
dysfunction.106 However, there is a need for more studies in this topic to clarify the modifying
effect of female gender in the association between endothelial dysfunction and diabetes.

6.3 ENDOTHELIAL DYSFUNCTION AND HYPERTENSION (MANUSCRIPT
2/CHAPTER 3)
The findings from our second manuscript of an association between sVCAM-1 and
hypertension is consistent with one previous prospective epidemiological study examining the
relationship between biomarkers of endothelial dysfunction and hypertension in those with type
1 diabetes86 and another cross-sectional study in the general population conducted in China.88
The observed association between endothelial dysfunction and hypertension may be due to
endothelial damage and related dysfunction impairing the vasodilator mechanism of
endothelium-derived relaxing factor (nitric oxide), subsequently causing elevated blood
pressure34. Endothelial dysfunction may also be related to other mechanisms involved in the
development of hypertension, including insulin resistance,64 systemic inflammation65 and
hyperuricemia.66 However, in our study, we also found that even though sVCAM-1 was
positively related to incident hypertension, sICAM-1 was not. While the reasons for these
differing associations between sVCAM-1 and sICAM-1 are not entirely clear, there are several
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hypotheses that can be postulated to explain this finding. It is possible that even though these
adhesion molecules are similar in structure they have different functions. For example, recent
animal studies have shown that VCAM-1, and not ICAM-1, plays a major role in the initiation of
atherosclerosis125, and others that have reported differential expression patterns for these
adhesion molecules in the vascular tree with VCAM-1 being expressed more in atherosclerotic
lesions whereas ICAM-1 expression extending into uninvolved aorta and lesion protected
regions.126 However, there is a need for more human studies to validate or refute our findings.

6.4 ENDOTHELIAL DYSFUNCTION AND CKD (MANUSCRIPT 3/CHAPTER 4)
The findings from our third manuscript showed that sVCAM-1 and sICAM-1 are not
independently related to incident CKD. We originally initiated this study because there was
strong biologically plausible data from animal studies to suggest that endothelial dysfunction
may have a role in the development of kidney disease. Janssen et al.145 reported that ICAM-1
knockout mice developed significantly less severe experimentally induced nephrotoxic nephritis
and glomerular crescents compared to control mice. Similarly, Kawasaki et al. showed that
injection of antibodies against ICAM-1 prevented glomerular injury in experimental crescentic
glomerular nephritis146. The importance of our study is that to our knowledge, this is the first
prospective study in humans to examine the association between endothelial dysfunction and the
development of renal disease using circulating levels of cellular adhesion molecules. Since
markers of endothelial dysfunction are known to be elevated secondarily in kidney disease89,90
and also as a result of hemodialysis163, the first line of treatment for late stages of kidney disease,
it is critically important to conduct a prospective study to investigate this association so as to
clarify the temporal nature of any associations detected. In our study, we found that even though
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there was a moderate positive association between sVCAM-1 and sICAM-1 and incident CKD in
the unadjusted model, the association was no longer present after adjusting for lifestyle and
medical risk factors. Therefore, our findings indirectly suggest that treatment/control of lifestyle
and medical risk factors for CKD such as higher BMI, diabetes, and hypertension should
continue to be the mainstay of treatment for CKD.

6.5 ENDOTHELIAL DYSFUNCTION AND CARDIOVASCULAR MORTALITY
(MANUSCRIPT 4/CHAPTER 5)
The findings from our fourth manuscript showed that sVCAM-1 and sICAM-1 levels are
positively associated with cardiovascular mortality. Previous studies have reported that markers
of endothelial dysfunction are associated with increased risk of developing cardiovascular
disease76,114,151 and cardiovascular mortality in ill subpopulations.91-93 However, since these
endothelial dysfunction markers are also known to be elevated secondary to these chronic
diseases89,90,163 (or as a result of treatments for these diseases), results from such studies of
patient cohorts may not reflect disease processes occurring in the general population. In the
current study, we found that markers of endothelial dysfunction are positively related to
cardiovascular mortality. Our finding is consistent with a previous report of an overall
association of markers of endothelial dysfunction and incident cardiovascular disease in the
Atherosclerosis Risk in Communities Study.114

6.6 SIGNIFICANCE OF THE STUDY
After exploring markers of endothelial dysfunction in relation to diabetes, hypertension,
CKD and cardiovascular mortality, endothelial dysfunction was shown to play a major role in all
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chronic disease outcomes under study except CKD. Clinically, these results suggest that treating
endothelial dysfunction may prevent diabetes, hypertension and cardiovascular mortality in
patients and in populations.

6.7 STRENGTHS AND LIMITATIONS
Since from an epidemiological pint of view, temporality is a major tenant of a truly
causal association, one important advantage of our study is the longitudinal nature of the Beaver
Dam Eye Study cohort dataset. The availability of long-standing prospective data on a
representative general population sample allowed us to elucidate the temporal nature of the
association between markers of endothelial dysfunction and the various cardiometabolic
outcomes we studied. This is especially important in the case of CKD where markers of
endothelial dysfunction are known to be elevated secondarily in later stages of kidney disease89,90
and also as a result of hemodialysis, a main stay of advanced CKD and end-stage renal disease
treatment.163 Another advantage of our study is the availability of a truly population-based
sample (as opposed to clinical patient populations). This is especially important in our study on
cardiovascular morality as markers of endothelial dysfunction are known to be elevated
secondarily in various disease states, such as those with rheumatoid arthritis and CKD.163 Other
strengths of the Beaver Dam Eye Study cohort include its high participation rate and use of
standardized protocols for exposure and outcome measurement and the availability of specific
serum markers of endothelial dysfunction, including sVCAM-1 and sICAM-1 levels. Our results
of positive and null associations between markers of endothelial dysfunction and incident
chronic disease outcomes and cardiovascular mortality possess strong internal validity as we
adjusted for and stratified by known confounders.
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A main study limitation is the limited generalizability of our study to other populations
as our study sample is a 99% white sample. Also since we used serum markers of endothelial
dysfunction, there is some potential for exposure misclassification which could under or
overestimate our results. Finally, as in any longitudinal study, it is possible that there are biases
related to selective survival (e.g. sick people dying more than healthy individuals), time-varying
confounding (e.g. a smoker at baseline may quit smoking , whereas a nonsmoker may start
smoking at a later date—which may affect their endothelial dysfunction marker level as well as
risk of diseases). Assuming that these changes are randomly distributed across levels of baseline
endothelial dysfunction marker, we believe that any misclassification is likely to be
nondifferential and likely to underestimate the true association.

6.8 FUTURE RESEARCH
To build upon our novel findings, we suggest that future investigations should include
assessing these relationships in ethnic diverse cohorts to assess whether or not the relationships
differ by ethnicity. For example, it is possible that some of the observed associations—
especially the association between endothelial dysfunction and hypertension—may vary by
race/ethnicity and that the difference in our findings to that in the literature may be explained by
such underlying racial/ethnic differences. Thus there is a need for future studies with adequate
sample sizes of various race/ethnicities to enable valid cross-ethnicity comparisons. Second, our
study measured these novel markers of endothelial dysfunction only in the baseline Beaver Dam
Eye Study cohort study samples. Since it is well known that levels of these markers may change
over time due to changing lifestyle, environmental, and biological factors, as a future research
topic, it is important to study the time varying effect of these markers of endothelial dysfunction
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by measuring them at multiple follow-up occasions in the same cohort. Lastly, it is important to
study the genetic factors that may predispose individuals to increased endothelial dysfunction in
response to lifestyle and environmental risk factors.

6.9 CONCLUSION
In summary, markers of endothelial dysfunction, including serum levels of sVCAM-1
and sICAM-1 were found to be associated with increased risk of developing diabetes mellitus in
men, and with hypertension and cardiovascular mortality in both men and women. However,
these markers of endothelial dysfunction were not found to be associated with the risk of
developing CKD, independent of known lifestyle and medical risk factors. Consequently, the
significance of our findings is that we are able to clarify the relationships between endothelial
dysfunction and various risk factors/mediators of cardiovascular mortality by examining them in
a single, large, population-based dataset. Our results point to the conclusion that endothelial
dysfunction may be related to cardiovascular mortality through its relation to diabetes mellitus
and hypertension but not to CKD.
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6.10 TABLES AND FIGURES
Table 6.1. Summary of Associations between Markers of Endothelial Dysfunction and Outcomes of Interest
sVCAM-1

sICAM-1

Overall

Men

Women

Overall

Men

Women

Diabetes Mellitus

+

+

-

+

+

-

Hypertension

+

+

+

-

-

-

Chronic Kidney Disease

-

-

-

-

-

-

Cardiovascular Mortality

+

-

+

+

-

-
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Endothelial
Dysfunction/Markers
of Endothelial
Dysfunction

Men

Women

+
-

+

Diabetes
Hypertension

Hypertension

+

-

+

Cardiovascular
Mortality

+
CKD
Figure 6. 1. The Mediation of Endothelial Dysfunction and Cardiovascular Mortality by Gender
Based on results from the four studies, we propose that endothelial dysfunction is related to
cardiovascular mortality through its relation to diabetes and hypertension in men, and through it
relation to hypertension in women, since endothelial dysfunction was not found to be related to
diabetes in them. Even though it is known that CKD is a risk factor for cardiovascular mortality, we
propose that CKD is not involved in the causal association between endothelial dysfunction and
cardiovascular mortality as we did not find an association between endothelial dysfunction and CKD.
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